denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Paar, K. E.
Paasi, G.
Paats, A. N.
Pabinger, I.
Pabst, C.
2179 - Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies – a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
Pabst, T.
114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
2413 - Therapy Management and Outcomes in Newly Diagnosed Unfit AML Patients Receiving Venetoclax + HMA – Insights from a Prospective Real-World Study in Switzerland and Austria
2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis
1504.2 - Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy
2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
2413 - Therapy Management and Outcomes in Newly Diagnosed Unfit AML Patients Receiving Venetoclax + HMA – Insights from a Prospective Real-World Study in Switzerland and Austria
2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis
1504.2 - Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy
Pacaud, L.
1026 - First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
3364 - Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma
3364 - Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma
Paccagnella, L.
Pacchiardi, K.
Pace, B. S.
Pacelli, P.
Pacenta, H.
Pacenta, H. L.
Pacheco, C. D.
Pacia, M.
Pacini, E.
Pacini, G.
Packard, R.
Packer, R.
Packman, K.
212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
Paczesny, S.
Paddison, F.
Paderi, J.
Padilla, C.
Padilla, J.
Padmanabhan, A.
1227 - Clonal Persistence of Anti-PF4 Antibodies in VITT Represents an MGTS-like State
1229 - A Subset of Antibodies to the Spike Protein's Receptor-Binding Domain in Severe COVID-19 Activate Platelets
1242 - Ticagrelor Interference in the Serotonin-Release Assay
3995 - Off-the-Shelf Cryopreserved Platelets to De-Risk Intravenous Immunoglobulin G (IVIg) Lots That Cause Platelet Activation
3996 - Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis
1229 - A Subset of Antibodies to the Spike Protein's Receptor-Binding Domain in Severe COVID-19 Activate Platelets
1242 - Ticagrelor Interference in the Serotonin-Release Assay
3995 - Off-the-Shelf Cryopreserved Platelets to De-Risk Intravenous Immunoglobulin G (IVIg) Lots That Cause Platelet Activation
3996 - Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis
Padmanabhan, A. A.
Padmanabhan, D.
Padron, E.
354 - High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms
481 - A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia
532 - A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1004 - CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
1520 - A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
1533 - Inflammatory Transcriptional Signature Can Discriminate De Novo and Secondary AML
1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
1843 - High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax – Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes
1845 - Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1del5q): Outcomes and Response to Treatment
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
3217 - Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
3227 - Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications
3228 - IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
3679 - Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4332 - Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)
4561 - Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4589 - The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS
4991 - A Deep-Learning Pipeline for Diagnosis of Myelodysplastic Syndromes/Neoplasms Using Bone Marrow Smears
5190 - Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
481 - A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia
532 - A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1004 - CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
1520 - A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
1533 - Inflammatory Transcriptional Signature Can Discriminate De Novo and Secondary AML
1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
1843 - High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax – Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes
1845 - Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1del5q): Outcomes and Response to Treatment
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
3217 - Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
3227 - Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications
3228 - IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
3679 - Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4332 - Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)
4561 - Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4589 - The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS
4991 - A Deep-Learning Pipeline for Diagnosis of Myelodysplastic Syndromes/Neoplasms Using Bone Marrow Smears
5190 - Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
Pagala, V.
Pagani, A.
Pagani, C.
453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
4473 - Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
4473 - Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience
Pagani, I. S.
991 - Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1, and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors
996 - Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure
2715 - Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity
996 - Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure
2715 - Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity
Pagani, M.
Pagarigan, B.
Page, C.
Page, D.
Page, E. C.
Page, G. P.
Page, K.
Pagel, J. M.
2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
5114 - Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
5114 - Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States
Pages, A.
474 - Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1289 - Emergence of DNA Damage Repair Clonal Hematopoiesis after Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
1289 - Emergence of DNA Damage Repair Clonal Hematopoiesis after Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
Pagis, V.
Pagliara, D.
3561 - Outcomes of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia Given Blinatumomab As Last Consolidation Treatment before Allogeneic Hematopoietic Cell Transplantation
4830 - CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)
4834 - Phase I/II Clinical Trial on CD19-Chimeric Antigen Receptor (CAR) T Cells Generated with an Automated Process, from Fresh Apheresis, and Reinfused As Fresh Drug Product for Pediatric/Young Adult Patients with Relapsed/Refractory (r/r) B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
4830 - CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)
4834 - Phase I/II Clinical Trial on CD19-Chimeric Antigen Receptor (CAR) T Cells Generated with an Automated Process, from Fresh Apheresis, and Reinfused As Fresh Drug Product for Pediatric/Young Adult Patients with Relapsed/Refractory (r/r) B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Pagliuca, S.
35 - First Results of High Throughput Pipeline for Serotypic and TCR Clonotypic Specificities in Aplastic Anemia and Large Granular Lymphocyte Leukemia Uncovering Antigenic Peptides Relevant to Disease Etiology
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
927 - Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models
2224 - Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes
4084 - An Immunogenetic Perspective on Bone Marrow Failure Syndromes: The KIR-HLA System
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
927 - Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models
2224 - Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes
4084 - An Immunogenetic Perspective on Bone Marrow Failure Syndromes: The KIR-HLA System
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
Pagnano, K. B.
Pahl, A. M.
Pai, A.
Pai, A. A.
2150 - Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis – Need for Dose Intensification
4879 - EASIXd0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis
4879 - EASIXd0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis
Paietta, E.
632 - PKCδ-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Paik, J.
Paik, J.
Paillard, C.
596 - Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study
1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
LBA-5 - Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities
1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
LBA-5 - Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities
Painschab, M. S.
2357 - Travel Time from Cancer Center Is Associated with Disparities in Non-Hodgkin Lymphoma Diagnosis Among People Living with HIV in Malawi
3005 - High Tumor Mutational Burden Associates with Increased CD8 T-Cell Presence, Decreased Tumor Heterogeneity, and Increased AICDA Expression in an HIV-Inclusive Cohort of Diffuse Large B-Cell Lymphoma
4344 - Immunogenomic Profiles of EBV-Associated Classic Hodgkin Lymphoma in an HIV-Inclusive Cohort
3005 - High Tumor Mutational Burden Associates with Increased CD8 T-Cell Presence, Decreased Tumor Heterogeneity, and Increased AICDA Expression in an HIV-Inclusive Cohort of Diffuse Large B-Cell Lymphoma
4344 - Immunogenomic Profiles of EBV-Associated Classic Hodgkin Lymphoma in an HIV-Inclusive Cohort
Paiva, B.
365 - Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
489 - Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis
670 - An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
900 - Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials
4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma
1927.1 - Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research
489 - Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis
670 - An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
900 - Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials
4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma
1927.1 - Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research
Pajarillo, R.
Pajwani, M. K.
Pakbaz, Z.
Pal Mudaranthakam, D.
Pal, R.
Pal, S.
Pal, S.
Palacio, C.
Palacio-Ramirez, S.
Palacios Barea, M. J.
Palacios-Berraquero, M. L.
3491 - Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma
4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma
4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)
Palandri, F.
242 - Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
658 - Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
997 - Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial
1090 - Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)
1754 - Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
3187 - Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison
3191 - Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials
3804 - Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States
4550 - Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients
1808.2 - POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
658 - Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
997 - Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial
1090 - Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)
1754 - Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
3187 - Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison
3191 - Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials
3804 - Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States
4550 - Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients
1808.2 - POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Palani, C. D.
Palani, R.
Palaniyandi, S.
Palao, S.
Palassery, R.
Palatty, R.
Palchaudhuri, R.
515 - In Vivo HSC Gene Editing for Correction of the Sickle Cell Mutation Using RNA Gene Writers
2197 - Delivery of Gene Writers In Vivo to Hematopoietic Stem Cells and T Cells Using Targeted and Untargeted Lipid Nanoparticles (LNP)
4799 - Targeted Lipid Nanoparticle Delivery of an RNA Gene Writer In Vivo Enables Generation of CAR-T Cells in a Humanized Mouse Model
2197 - Delivery of Gene Writers In Vivo to Hematopoietic Stem Cells and T Cells Using Targeted and Untargeted Lipid Nanoparticles (LNP)
4799 - Targeted Lipid Nanoparticle Delivery of an RNA Gene Writer In Vivo Enables Generation of CAR-T Cells in a Humanized Mouse Model
Paleja, K.
Palermo, M. G.
Palfreyman, E.
Palhais, B.
Palich, R.
Palihati, M.
Palis, J.
Palkar, P.
Palladini, G. O.
287 - Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
1927 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
4400 - Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study
1927.1 - Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
1927 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
4400 - Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study
1927.1 - Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research
Palladino, A.
716 - Descriptive Characterization of Bleeding Events in Participants with Severe Hemophilia Α or B without Inhibitors, Receiving Prophylactic Marstacimab Treatment
1210 - Safety Biomarkers in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Without Inhibitors Receiving Prophylactic Marstacimab Treatment: Results From the Phase 3 BASIS Trial
1210 - Safety Biomarkers in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Without Inhibitors Receiving Prophylactic Marstacimab Treatment: Results From the Phase 3 BASIS Trial
Pallas, C.
Pallasch, C.
Palle, J.
Palma, L. C.
Palme, I.
Palmer, A.
Palmer, J.
244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
440 - Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
1794 - Utilizing Large Language Models to Automate Prognostication in Patients with Myelofibrosis: A Retrospective Cohort Study
1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4559 - Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
5195 - Predictors of Individual Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study
440 - Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
1794 - Utilizing Large Language Models to Automate Prognostication in Patients with Myelofibrosis: A Retrospective Cohort Study
1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4559 - Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
5195 - Predictors of Individual Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study
Palmer, J. M.
Palmer, T. D.
Palmieri, R.
Palmisiano, N. D.
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
214 - Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
2880 - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
214 - Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
2880 - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Palmqvist, L.
Palo, W.
Palomares, K.
Palomba, L.
238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
340 - Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
781 - Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center
912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
3125 - Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3128 - A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort
3453 - A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)
3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease
- T-cell–based Therapies for Treating Relapsed or Refractory Mantle Cell Lymphoma
340 - Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
781 - Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center
912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
3125 - Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3128 - A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort
3453 - A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)
3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease
- T-cell–based Therapies for Treating Relapsed or Refractory Mantle Cell Lymphoma
Palomera, L.
489 - Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis
1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials
1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials
Palomo, L.
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1935 - Ultra-Deep Sequencing of TP53 in Multiple Myeloma: Double-Hit Prevalence and Clinical Phenotype
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1935 - Ultra-Deep Sequencing of TP53 in Multiple Myeloma: Double-Hit Prevalence and Clinical Phenotype
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
Palomo, L.
Palomo, M.
Palomo Moraleda, P.
Palomo Rumschisky, P.
3349 - Clinical, Biological and Prognostic Characterization of Multiple Myeloma According to the Presence of Circulating Plasma Cells
3491 - Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
3491 - Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
Paludo, J.
236 - Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
387 - Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma
1626 - High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma
1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
3728 - Duration of Therapy in Patients with Waldenström Macroglobulinemia Undergoing Dose Reductions of First-Line Ibrutinib: A Real-World Analysis
5204 - Call Me Maybe: An Analysis of Hematology Fellowship Home-Call Burden, Perceptions, and Attitudes
387 - Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma
1626 - High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma
1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
3728 - Duration of Therapy in Patients with Waldenström Macroglobulinemia Undergoing Dose Reductions of First-Line Ibrutinib: A Real-World Analysis
5204 - Call Me Maybe: An Analysis of Hematology Fellowship Home-Call Burden, Perceptions, and Attitudes
Palumbo, G. A.
Palumbo, G. A.
Palumbo, G. A. M.
Palumbo, J. S.
Pammer, P.
Pampena, M. B.
Pamuk, G.
Pan, H.
345 - Mitochondrial Transcriptional-Translational Conflict Contributes to Defective Erythropoiesis and Disease Progression in Splicing Factor Mutant Myelodysplastic Syndromes
682 - CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
2697 - Anti-CD38 Monoclonal Antibody Is a Salvage Regimen in Relapsed/Refractory Aplastic Anemia
4029 - Daratumumab Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia: A Pilot Trail
4961 - Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBBT87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients
682 - CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
2697 - Anti-CD38 Monoclonal Antibody Is a Salvage Regimen in Relapsed/Refractory Aplastic Anemia
4029 - Daratumumab Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia: A Pilot Trail
4961 - Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBBT87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients
Pan, H.
Pan, J.
Pan, J.
PAN, J.
2058 - Development of a Novel Allogeneic Super-Γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors
3466 - Safety and Feasibility of Intrathecal Infusion of CD19 and/or CD22 CAR T Cells in r/r B-ALL Patients with CNSL or High-Risk CNS Relapse
4785 - Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-in-One Site-Specific Integration Technology for Autoimmune Diseases
3466 - Safety and Feasibility of Intrathecal Infusion of CD19 and/or CD22 CAR T Cells in r/r B-ALL Patients with CNSL or High-Risk CNS Relapse
4785 - Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-in-One Site-Specific Integration Technology for Autoimmune Diseases
PAN, J.
Pan, L.
Pan, L.
Pan, L.
Pan, L.
Pan, M.
877 - Luspatercept Promotes Heme Biosynthesis and Erythroblast Island Formation in a Novel Low-Risk MDS Mouse Model
2488 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in Townes SCD Mouse Model
4035 - Loss of Cpt1a Results in Elevated Mitochondrial Reactive Oxygen Species from Glucose-Fueled Mitochondrial Oxidative Phosphorylation and Defective Hematopoietic Stem Cells
4140 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in a Mouse MDS Model of an Inducible Mutant c-Myc Knock-in
2488 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in Townes SCD Mouse Model
4035 - Loss of Cpt1a Results in Elevated Mitochondrial Reactive Oxygen Species from Glucose-Fueled Mitochondrial Oxidative Phosphorylation and Defective Hematopoietic Stem Cells
4140 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in a Mouse MDS Model of an Inducible Mutant c-Myc Knock-in
Pan, S. S.
Pan, T.
1305 - Deciphering Transcriptome Alterations in Bone Marrow Hematopoiesis at Single-Cell Resolution in Prolonged Thrombocytopenia after Umbilical Cord Blood Transplantation
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
Pan, W.
Pan, X. Z.
Pan, X.
Pan, Y.
503 - Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy
4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy
4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy
Pan, Y.
Pan, Z.
969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
2917 - Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data
4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
2917 - Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data
4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma
Pan, Z.
Pan, Z.
2139 - Using T-Lymphocyte Subsets at Engraftment to Predict the Risk of Acute Graft Versus Host Disease in Patients with Thalassemia Major：Development of a New Predictive Nomogram
2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China
2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China
Pan, Z.
Pan-Hammarström, Q.
Panagiota, V.
Panahi, A.
Panahi, N.
Panaro, K. M.
Panaroni, C.
Panayiotidis, P.
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
LBA-1 - Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
LBA-1 - Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
Pancari, P. A.
Panch, S.
22 - Anti-HLA Antibody Specificities Are Differentially Associated with Immune Platelet Transfusion Refractoriness in Patients at Lower Calculated Panel Reactive Antibody (cPRA) Levels
124 - T-Cell Transcriptomic Signatures in Adults with Primary Untreated Immune Thrombocytopenia Segregate By Age, Revealing Distinct Druggable Pathways
3526 - Presence of Anti-D and Passive Transfer of Anti-D in Bone Marrow Transplant Patients Does Not Affect Transplant Outcomes
- Medical Educators in Hematology
124 - T-Cell Transcriptomic Signatures in Adults with Primary Untreated Immune Thrombocytopenia Segregate By Age, Revealing Distinct Druggable Pathways
3526 - Presence of Anti-D and Passive Transfer of Anti-D in Bone Marrow Transplant Patients Does Not Affect Transplant Outcomes
- Medical Educators in Hematology
Panch, S.
Panchal, M.
Panckeri, K.
Panda, P.
Panda, T.
Pandey, A.
Pandey, A.
Pandey, A. S.
Pandey, N.
Pandey, P.
Pandey, S.
Pandey, T.
Pandhi, A.
Pandit-Taskar, N.
Pandolfi, P. P.
Pandrangi, K.
Pandyra, A. A.
Pane, F.
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
992 - Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network
1809 - A Study on the Effect of Luspatercept on Regulatory T Cells and Myeloid Derived Suppressor Cells in Low Risk Myelodysplastic Syndrome with Ring Sideroblasts
2427 - Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)
2463 - Advancing Diagnostic Accuracy and Lowering Idiopathic Erythrocytosis Rates through Next-Generation Sequencing
2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
992 - Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network
1809 - A Study on the Effect of Luspatercept on Regulatory T Cells and Myeloid Derived Suppressor Cells in Low Risk Myelodysplastic Syndrome with Ring Sideroblasts
2427 - Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)
2463 - Advancing Diagnostic Accuracy and Lowering Idiopathic Erythrocytosis Rates through Next-Generation Sequencing
2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
Paneesha, S.
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
585 - IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study
749 - Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
585 - IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study
749 - Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Paneesha, S.
Panepinto, J. A.
Paner-Straseviciute, A.
Pang, A.
2127 - Efficacy and Safety of a Modified Conditioning Regimen Based on Mitoxantrone Hydrochloride Liposome and Busulfan/Cyclophosphamide for Patients with Refractory and Relapsed Acute Myeloid Leukemia
2144 - The Comparison between Chimeric Mouse-Human and Humanized Anti-CD25 Monoclonal Antibody for Steroid-Refractory Acute Graft-Versus-Host Disease
2828 - Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation
2144 - The Comparison between Chimeric Mouse-Human and Humanized Anti-CD25 Monoclonal Antibody for Steroid-Refractory Acute Graft-Versus-Host Disease
2828 - Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation
Pang, Y.
2053 - CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma
2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy
5194 - Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results
2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy
5194 - Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results
Pangault, C.
Panicker, S.
805 - ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis
3981 - A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding
3981 - A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding
Panicker, S. R.
Panigada, M.
Panigrahi, A. R.
Panigrahi, K.
Panitsas, F.
Pannagl, K.
Pannunzio, A.
Panopoulou, A.
Panossian, M.
Panousi, E.
Panozo, M.
Panse, J.
1313 - Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab
1317 - Characterization of Erythrocytes in PNH: Can We Predict Response to Complement Inhibition Based on Different Erythrocyte Markers?
2321 - The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment
2692 - Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial
4072 - Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
4078 - Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab
4082 - The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate
5085 - Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
1317 - Characterization of Erythrocytes in PNH: Can We Predict Response to Complement Inhibition Based on Different Erythrocyte Markers?
2321 - The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment
2692 - Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial
4072 - Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
4078 - Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab
4082 - The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate
5085 - Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
Pansu, N.
Pantaleo, A.
Pantazi, J.
Panteli, C.
Panteliadou, A. K.
1163 - Long-Term Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Patients with Progressive Systemic Sclerosis
3408 - Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
3484 - Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation
4778 - Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease
3408 - Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
3484 - Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation
4778 - Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease
Pantin, J.
Panton, G.
Paoli, C.
Paolini, S.
2893 - Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
2916 - T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia
3800 - Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms
2916 - T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia
3800 - Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms
Paoloni, F. P.
274 - Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia
1872 - Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi
4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
1872 - Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi
4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
Papa, P.
Papachristou, E. K.
Papadaki, E.
Papadaki, H. A.
Papadakis, S.
Papadantonakis, N.
Papademetriou, E.
Papadimitriou, M.
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
1607 - Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy
1899 - Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies
3276 - Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
1607 - Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy
1899 - Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies
3276 - Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
Papadimitriou, M.
247 - Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
766 - Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
766 - Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
Papadimou, A.
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1600 - Genomic Characterization of Ibrutinib-Resistant Waldenström’s Macroglobulinemia
1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations
1600 - Genomic Characterization of Ibrutinib-Resistant Waldenström’s Macroglobulinemia
1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations
Papadopoulos, A. M.
Papadopoulos, E. B.
267 - Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies
686 - Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies
686 - Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies
Papadopoulos, I.
Papadopoulos, V.
Papadopoulou, A.
Papadopoulou, T.
Papaemmanuil, E.
190 - Delayed Trp53 Activation Protects Dnmt3a-Mutant Haematopoietic Stem Cells from Inflammatory Attrition
1589 - Genomic Characterization and Classification of BCL6 Rearranged Follicular Lymphomas
1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count
3198 - Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms
1589 - Genomic Characterization and Classification of BCL6 Rearranged Follicular Lymphomas
1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count
3198 - Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms
Papageorgiou, S. G.
1083 - High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
Papaioannou, D.
951 - CRISPR/RfxCas13d Screening Identifies the Long Non-Coding RNA (LncRNA) Nfyc-AS1 As a Molecular Vulnerability in Acute Myeloid Leukemia (AML)
954 - A Protein-Coding Circular RNA That Regulates DNA Damage Response in BCR::ABL-Positive Leukemias
4130 - Isoform-Level Long Noncoding RNA Dependencies in Multiple Myeloma
954 - A Protein-Coding Circular RNA That Regulates DNA Damage Response in BCR::ABL-Positive Leukemias
4130 - Isoform-Level Long Noncoding RNA Dependencies in Multiple Myeloma
Papaioannou, M.
1317 - Characterization of Erythrocytes in PNH: Can We Predict Response to Complement Inhibition Based on Different Erythrocyte Markers?
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
Papajik, T.
Papalexandri, A.
3408 - Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
3484 - Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation
4778 - Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease
3484 - Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation
4778 - Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease
Papanikolaou, A.
Papapetrou, E.
873 - Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells
1293 - iPSC Reprogramming Identifies the Role of Cryptic Drivers in Preleukemic Clonal Evolution
1379 - AML Derived Induced Pluripotent Stem Cells Reveal a Genotype-Independent Effect of Monocytic Differentiation in Mediating Venetoclax Resistance
2749 - Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
4045 - Dnmt3a and Tet2-Driven Clonal Hematopoiesis Have Opposing Effects on the Pathogenesis of Alzheimer’s Disease
- Modeling Blood Disorders Using Human Pluripotent Stem Cells
1293 - iPSC Reprogramming Identifies the Role of Cryptic Drivers in Preleukemic Clonal Evolution
1379 - AML Derived Induced Pluripotent Stem Cells Reveal a Genotype-Independent Effect of Monocytic Differentiation in Mediating Venetoclax Resistance
2749 - Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
4045 - Dnmt3a and Tet2-Driven Clonal Hematopoiesis Have Opposing Effects on the Pathogenesis of Alzheimer’s Disease
- Modeling Blood Disorders Using Human Pluripotent Stem Cells
Paparini, S.
Papassotiriou, I.
2587 - Circulating and Synovial Fluid Levels of YKL-40 Protein in Patients with Hemophilia and Arthropathy: Preliminary Observations
3408 - Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
3408 - Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
Papathanasiou, M.
Papathanasiou, M.
Papatsirou, M.
Papayannidis, C.
211 - Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
2825 - Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2893 - Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
2916 - T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia
5188 - Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
2825 - Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2893 - Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
2916 - T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia
5188 - Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
Papayannidis, C.
113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
2821 - Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
2821 - Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
Papo, M.
Papoin, J.
195 - Hematopoietic Stem Cells Supporting Fetal Erythropoiesis Are Differentially Regulated By Small and Large Ribosomal Subunits
1076 - Dexamethasone Targets E2F4 to Induce Erythroid Progenitor Renewal
2455 - Comprehensive Analysis of Changes in the Proteome during Maturation of Nascent Human Bone Marrow Reticulocytes into Red Cells
1076 - Dexamethasone Targets E2F4 to Induce Erythroid Progenitor Renewal
2455 - Comprehensive Analysis of Changes in the Proteome during Maturation of Nascent Human Bone Marrow Reticulocytes into Red Cells
Papotti, R.
Papoutselis, M. K.
Papp, E.
887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
Papp, T. E.
Pappa, V.
1083 - High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
Papuga, J.
Papyan, R.
Paquette, R.
2104 - Comparison of Tacrolimus/Methotrexate and Post-Transplant Cyclophosphamide Graft-Versus Host Disease Prophylaxis for Haploidentical and Matched Allogeneic Stem Cell Transplantation Demonstrates Improved Overall Survival and Reduced Mortality, Shorter Length of Stay, Less Peritransplant Toxicity with Post-Transplant Cyclophosphamide
3922 - Multiplex Analysis of Peripheral Blood in Cancer Patients Predicts Humoral and Cellular Responses to Sars-Cov-2 Vaccines
4202 - Concurrent Blinatumomab and Human Leukocyte Antigen-Mismatched Cellular Therapy in Patients with High-Risk B-Cell Acute Lymphoblastic Leukemia, a Phase I Prospective Cohort Study
3922 - Multiplex Analysis of Peripheral Blood in Cancer Patients Predicts Humoral and Cellular Responses to Sars-Cov-2 Vaccines
4202 - Concurrent Blinatumomab and Human Leukocyte Antigen-Mismatched Cellular Therapy in Patients with High-Risk B-Cell Acute Lymphoblastic Leukemia, a Phase I Prospective Cohort Study
Parachalil Gopalan, B.
Paralkar, V. R.
Paramore, C.
Paran, F. J.
Parapatt, G. K.
Parascondola, A.
Parasole, R.
Parchinsky, V.
Parchment, R.
Pardal De La Mano, E.
4403 - Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?
Pardal, E.
Pardanani, A. D.
244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
1785 - Revised International Working Group Risk Model for Survival in Polycythemia Vera
1797 - The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates
1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
1827 - Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
3169 - Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts
3171 - Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities
3176 - Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
3185 - Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4552 - Cancers in Polycythemia Vera and Essential Thrombocythemia: A before and after Diagnosis Survey and Analysis of Risk Factors
4586 - PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival
1785 - Revised International Working Group Risk Model for Survival in Polycythemia Vera
1797 - The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates
1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
1827 - Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
3169 - Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts
3171 - Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities
3176 - Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
3185 - Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4552 - Cancers in Polycythemia Vera and Essential Thrombocythemia: A before and after Diagnosis Survey and Analysis of Risk Factors
4586 - PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival
Pardee, T. S.
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
1729 - Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma
2858 - The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia
1729 - Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma
2858 - The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia
Pardeshi, A.
Pardo, L.
Pardo, L.
405 - The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC
5148 - Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
5148 - Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
Pardo, M. R.
64 - Deciphering the AML Niche: RNA Sequencing and Spatial Transcriptomics Reveal Diverse Transcriptomic Landscapes in Responders Vs. Non-Responders
754 - Engrafted JAK2V617F Clone Hijacks Resident Non-Mutated Hematopoietic System to Drive Myeloproliferative Neoplasm
1614 - Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma
1644 - Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study
754 - Engrafted JAK2V617F Clone Hijacks Resident Non-Mutated Hematopoietic System to Drive Myeloproliferative Neoplasm
1614 - Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma
1644 - Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study
Pardo Sanz, A.
Pardy, N.
Paredes, J.
Paredes, R.
Paredes, S.
983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
1718 - Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study
4452 - Extranodal NK/T-Cell Lymphoma in Latin America: A Retrospective Multinational Analysis of Clinical Features, Therapeutic Approaches and Outcomes from the Latin American Group of Lymphoproliferative Disorders (GELL)
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
1718 - Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study
4452 - Extranodal NK/T-Cell Lymphoma in Latin America: A Retrospective Multinational Analysis of Clinical Features, Therapeutic Approaches and Outcomes from the Latin American Group of Lymphoproliferative Disorders (GELL)
Parekh, A.
Parekh, C.
1418 - TBL1 Inhibition Eradicates Drug Resistant Leukemia Initiating Cells in T-ALL
1435 - T-Cell Receptor Signaling and Dysfunction during Blinatumomab Therapy in Pediatric Acute Lymphoblastic Leukemia
2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch
4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study
1435 - T-Cell Receptor Signaling and Dysfunction during Blinatumomab Therapy in Pediatric Acute Lymphoblastic Leukemia
2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch
4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study
Parekh, D.
Parekh, S.
332 - Prevention of Antigen Escape By Modulation of Off-Target Tumor Killing in T Cells
357 - Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab
589 - BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies
1402 - Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance
1970 - Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway
2231 - Novel Liquid Biopsy Approach for Detection and Characterization of Disease Progression of Plasma Cell Disorders
3259 - Improving Anti-BCMA CAR-T Functionality with Novel Celmods in Multiple Myeloma
3329 - Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation
4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients
4658 - Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis
4691 - Monovalent XBB1.5 Vaccination Augments Humoral and Cellular Immunity to Novel Sars-Cov-2 Variants in Immunocompromised Patients with Multiple Myeloma
357 - Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab
589 - BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies
1402 - Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance
1970 - Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway
2231 - Novel Liquid Biopsy Approach for Detection and Characterization of Disease Progression of Plasma Cell Disorders
3259 - Improving Anti-BCMA CAR-T Functionality with Novel Celmods in Multiple Myeloma
3329 - Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation
4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients
4658 - Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis
4691 - Monovalent XBB1.5 Vaccination Augments Humoral and Cellular Immunity to Novel Sars-Cov-2 Variants in Immunocompromised Patients with Multiple Myeloma
Parent, E. E.
Parfenova, E.
Parhiz, H.
Parikh, A.
Parikh, E. N.
Parikh, J.
Parikh, K.
Parikh, S. A.
397 - Prevalence, Genetic Predispositions and Clinical Consequences of Non-CLL-Type MBL: Screening in 10,330 Individuals
784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4606 - Rewiring Cancer Drivers to Induce Apoptosis By Transcriptional Chemical Inducers of Proximity in Chronic Lymphocytic Leukemia
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)
5038 - First-Line Treatment Choice and Risk of Other Malignancies in US Veterans Diagnosed with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4606 - Rewiring Cancer Drivers to Induce Apoptosis By Transcriptional Chemical Inducers of Proximity in Chronic Lymphocytic Leukemia
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)
5038 - First-Line Treatment Choice and Risk of Other Malignancies in US Veterans Diagnosed with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
Parikh, S.
Parikh, S.
511 - An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
4888 - A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)
4956 - Rheological Comparison of Red Cells from Individuals with SCD Treated with Gene Therapy, Haploidentical Transplantation or Hydroxyurea
4888 - A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)
4956 - Rheological Comparison of Red Cells from Individuals with SCD Treated with Gene Therapy, Haploidentical Transplantation or Hydroxyurea
Parilla, D.
Paris, L.
674 - Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial
4732 - Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study
4732 - Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study
Parisi, M.
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
Parisi, S.
Park, A. S.
Park, A. S.
Park, C. Y.
Park, C. S.
Park, C. Y.
2234 - Self-Supervised Learning Based Characterization of Bone Marrow Biopsies for Enhanced Diagnosis of Hematologic Disorders
2989 - Lymph Node Stromal Cells Underlie the Clinicopathologic Features of Castleman Disease
3608 - AI-Powered Evaluation of Bone Marrow Biopsies Can Distinguish Myeloid Neoplasms from Clinical Mimics
3916 - Self-Supervised Learning Model Accurately Diagnoses Hemophagocytic Lymphohistiocytosis from Histology Images
2989 - Lymph Node Stromal Cells Underlie the Clinicopathologic Features of Castleman Disease
3608 - AI-Powered Evaluation of Bone Marrow Biopsies Can Distinguish Myeloid Neoplasms from Clinical Mimics
3916 - Self-Supervised Learning Model Accurately Diagnoses Hemophagocytic Lymphohistiocytosis from Histology Images
Park, H.
4339 - Genome-Wide Meta-Analysis Identifies Multiple Germline Genetic Variants Associated with Increased Risk of Follicular Lymphoma
4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)
4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)
Park, J. H.
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
781 - Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center
912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
963 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes
1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)
1604 - Transcriptomic and Epigenomic Landscape of Hairy Cell Leukemia at Single-Cell Resolution
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy
2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
3128 - A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort
3458 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease
4837 - Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)
4845 - Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial
781 - Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center
912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
963 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes
1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)
1604 - Transcriptomic and Epigenomic Landscape of Hairy Cell Leukemia at Single-Cell Resolution
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy
2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
3128 - A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort
3458 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease
4837 - Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)
4845 - Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial
Park, J. E.
Park, J.
Park, J. H.
Park, J. S.
Park, J. I.
Park, J. H.
Park, M.
Park, N.
Park, N.
Park, R.
Park, S. K.
Park, S.
4220 - Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia
Park, S. Y.
4220 - Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
5048 - Discrete Choice Experiment to Assess Treatment Preferences of Patients with Multiple Myeloma, Their Caregivers, and Physicians in Korea (CAREMM-2304)
5048 - Discrete Choice Experiment to Assess Treatment Preferences of Patients with Multiple Myeloma, Their Caregivers, and Physicians in Korea (CAREMM-2304)
Park, S.
118 - The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe
349 - Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial
1826 - A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)
1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
349 - Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial
1826 - A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)
1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
Park, S. I.
458 - PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601
2053 - CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma
2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy
2053 - CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma
2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy
Park, S. M.
Park, S. J.
Park, S. S.
1310 - Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis
4220 - Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
4707 - Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia
4977 - Transcriptional Profiling of Plasma Cells in AL Amyloidosis and Multiple Myeloma: A Single-Cell RNA Sequencing Approach
5048 - Discrete Choice Experiment to Assess Treatment Preferences of Patients with Multiple Myeloma, Their Caregivers, and Physicians in Korea (CAREMM-2304)
4220 - Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
4707 - Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia
4977 - Transcriptional Profiling of Plasma Cells in AL Amyloidosis and Multiple Myeloma: A Single-Cell RNA Sequencing Approach
5048 - Discrete Choice Experiment to Assess Treatment Preferences of Patients with Multiple Myeloma, Their Caregivers, and Physicians in Korea (CAREMM-2304)
Park, T.
Park, Y.
3170 - Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon
3942 - Impact of Platelet Transfusion and Bleeding Risk Stratification in Patients with Immune Thrombocytopenia before Procedures: A Nationwide Population-Based Cohort Study
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
3942 - Impact of Platelet Transfusion and Bleeding Risk Stratification in Patients with Immune Thrombocytopenia before Procedures: A Nationwide Population-Based Cohort Study
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
Park, Y.
Park, Y. H.
1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
1799 - Ropeginterferon in Low-Risk Patients with Polycythemia Vera
3170 - Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon
1799 - Ropeginterferon in Low-Risk Patients with Polycythemia Vera
3170 - Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon
Parker, A. C.
Parker, C.
Parker, H.
Parker, M. P.
Parker, M. H.
Parker, T. L.
3378 - Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
3309.1 - A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
3309.1 - A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Parker, Y.
Parkinson, K.
Parkman, R.
Parks, A.
Parks, A. L.
Parks, C.
Parma, M.
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
Parmar, B.
Parmar, G.
1975 - Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study
3352 - Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
3352 - Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
Parmar, H.
861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)
1946 - Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)
2408 - Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis
3316 - Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
1946 - Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)
2408 - Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis
3316 - Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
Parmar, K.
Parmar, S.
Parmentier, A.
Parmentier, S. B.
Parmigiani, G.
Parodi, A.
1471 - Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification
1478 - High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction
1482 - Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease
1478 - High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction
1482 - Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease
Parot, X.
Parovichnikova, E.
Parpia, S.
Parquet, N.
Parra, F.
Parras, J.
Parrinello, C. M.
3756 - Symptoms Detection Among Patients with Lymphoid Malignancies (LM) Using Electronic Patient-Reported Outcomes (ePROs) in Community Hematology-Oncology Clinics
5046 - Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy
5046 - Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy
Parrish, C.
385 - Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma – an Economic Evaluation of the Fitness Trial
673 - IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
673 - IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
Parrondo, R. D.
704 - Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
3770 - Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results
3790 - Disparities in Multiple Myeloma (MM): Race/Ethnicity-Specific Sociodemographic and Economic Factors That May Drive Patient Decisions to Refuse Treatment
4723 - Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Sociodemographic and Economic Factors Contributing to the Disparity
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
3770 - Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results
3790 - Disparities in Multiple Myeloma (MM): Race/Ethnicity-Specific Sociodemographic and Economic Factors That May Drive Patient Decisions to Refuse Treatment
4723 - Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Sociodemographic and Economic Factors Contributing to the Disparity
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
Parrow, N. L.
Parry, A.
478 - 18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting
3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)
3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)
Parry, E. M.
335 - SEC62 Regulates HLA-E Expression in Diffuse Large B-Cell Lymphoma to Function As a Mechanism of Immune Evasion
645 - Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma
761 - Polyfunctional Effector PD-1+ CD8+ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models
1669 - Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade
4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL
4628 - A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
645 - Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma
761 - Polyfunctional Effector PD-1+ CD8+ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models
1669 - Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade
4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL
4628 - A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
Parsegov, B.
Parsons, A.
Parsons, B. M.
Parsons, S. K.
567 - Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium
785 - Churn, Churn Churn! a Mixed Methods Analysis of Young Adult Leukemia and Lymphoma Survivors’ Experience Navigating the Insurance Landscape in a Post Affordable Care Act Era
785 - Churn, Churn Churn! a Mixed Methods Analysis of Young Adult Leukemia and Lymphoma Survivors’ Experience Navigating the Insurance Landscape in a Post Affordable Care Act Era
Parsons, T. M.
Parthiban, N.
Partouche, S.
Paruzzo, L.
4 - Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate
1750 - Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5th Edition of the Who Classification
3779 - Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma
4504 - CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia
4792 - EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors
1750 - Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5th Edition of the Who Classification
3779 - Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma
4504 - CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia
4792 - EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors
Parvataneni, T.
Parvin, S.
Parzych, S. E.
Pasala, A. R.
Pasalic, L.
Pasanen, A.
235 - Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich
747 - Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial
747 - Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial
Pasanisi, A.
Pasauliene, R.
Pasca, S.
Pascal, L.
Pascale, S. P.
Pascarella, A.
Pasciolla, C.
113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
Pascual Izquierdo, C.
Pascual Izquierdo, M. C.
5 - Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)
713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)
1183 - Use of Steroids in Subjects with ITP in Spain: Duration and Toxicity
2618 - ADAMTS13 Activity Measurement Using a Chemiluminescence-Based Technique. Prospective Multicenter Comparative Study of the Spanish Apheresis Group (GEA)- Spanish Society of Hematology and Hemotherapy (SEHH)
3948 - Investigating the Effectiveness and Safety of Combining Thrombopoietin Receptor Agonist and Immunosuppressant Drugs for Patients with Multirefractory Immune Thrombocytopenia after Second-Line Monotherapy Treatments
3999 - Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)
713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)
1183 - Use of Steroids in Subjects with ITP in Spain: Duration and Toxicity
2618 - ADAMTS13 Activity Measurement Using a Chemiluminescence-Based Technique. Prospective Multicenter Comparative Study of the Spanish Apheresis Group (GEA)- Spanish Society of Hematology and Hemotherapy (SEHH)
3948 - Investigating the Effectiveness and Safety of Combining Thrombopoietin Receptor Agonist and Immunosuppressant Drugs for Patients with Multirefractory Immune Thrombocytopenia after Second-Line Monotherapy Treatments
3999 - Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)
Pascual, M. J.
2105 - Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)
4884 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth
4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)
4884 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth
Pascual, M. J.
597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis
598 - HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
2188 - Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
3531 - Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
598 - HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
2188 - Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
3531 - Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
Pashkovskaia, T.
Pasic, I.
687 - Survival and Engraftment Post Allogeneic Hematopoietic Stem Cell Transplantation: ABO Mismatch Matters in RIC
2151 - The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes
2183 - Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion
4863 - Strength to Endure: Superiority of MAC over RIC in Patients <65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis
4865 - Haploidentical and Mismatched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Cohort Study
4883 - Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis
4896 - Monocytes Matter: Impact of Monocyte Recovery on Allogeneic Hematopoietic Stem Cell Transplant Outcomes with Post-Transplantation Cyclophosphamide As Graft Versus Host Disease Prophylaxis
4899 - Identification of High-Risk Patients and Establishment of a Clinical Prediction Model for Frontline Steroid Failure in Chronic Graft-Versus-Host-Disease
2151 - The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes
2183 - Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion
4863 - Strength to Endure: Superiority of MAC over RIC in Patients <65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis
4865 - Haploidentical and Mismatched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Cohort Study
4883 - Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis
4896 - Monocytes Matter: Impact of Monocyte Recovery on Allogeneic Hematopoietic Stem Cell Transplant Outcomes with Post-Transplantation Cyclophosphamide As Graft Versus Host Disease Prophylaxis
4899 - Identification of High-Risk Patients and Establishment of a Clinical Prediction Model for Frontline Steroid Failure in Chronic Graft-Versus-Host-Disease
Pasikhova, Y.
Paskett, E. D.
Paskevicius, J.
Pasquale, R.
Pasqualucci, L.
Pasquer, H.
Pasquet, M.
310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
LBA-2 - Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
LBA-2 - Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis
Pasquier, F.
Pasquini, M. C.
71 - Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)
81 - 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702
470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
472 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
527 - Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
609 - Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
930 - Uncovering the Genetics of Poor and Exceptional Survivorship after Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)
1039 - Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
81 - 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702
470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
472 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
527 - Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
609 - Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
930 - Uncovering the Genetics of Poor and Exceptional Survivorship after Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)
1039 - Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
Pasricha, S. R.
Passafiume, D.
Passam, F. H.
1233 - Platelet Endoplasmic Reticulum Stress Promotes Thrombosis in an in Vitro Laser-Induced Endothelial Injury Model
2578 - Disulfide Bond Heterogeneity in Factor VIII: Implications for Protein Function and Haemophilia a Therapy
3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo
2578 - Disulfide Bond Heterogeneity in Factor VIII: Implications for Protein Function and Haemophilia a Therapy
3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo
Passamonti, F.
Passamonti, F.
482 - Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial
1086 - Toward the Creation of Diagnostic Algorithms for Congenital Hemolytic Anemia Using Advanced Parameters from Modern Hematology Analyzers
2928 - Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level
1808.2 - POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
1086 - Toward the Creation of Diagnostic Algorithms for Congenital Hemolytic Anemia Using Advanced Parameters from Modern Hematology Analyzers
2928 - Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level
1808.2 - POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Passamonti, F.
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1696 - Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center
1854 - Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1696 - Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center
1854 - Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia
Passaro, D.
Passerini, V.
2957 - High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies
4382 - Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment
4382 - Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment
Passero, Jr., F.
Passet, M.
Passi, A.
Passweg, Sr., J.
73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
607 - Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
2161 - Comparative Safety and Efficacy of Posttransplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Cardiovascular Comorbidity Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission from Unrelated Donors: A Retrospective Pair-Match Analysis of EBMT ALWP
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3559 - Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
607 - Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
2161 - Comparative Safety and Efficacy of Posttransplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Cardiovascular Comorbidity Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission from Unrelated Donors: A Retrospective Pair-Match Analysis of EBMT ALWP
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3559 - Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
Passweg, J. R.
508 - Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT
2185 - Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party
2185 - Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party
Pastor Galan, I.
Pastor Loyola, V. B.
Pastorczak, A.
Pastore, D.
2126 - Evidence-Based Choice of Conditioning Regimen for Hematopoietic Stem Cell Transplantation (HSCT) in Acute Leukemia: The Italian Cellular Therapy and Stem Cell Transplant Group (GITMO) Guidelines
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
Pastore, Y. D.
Pastoret, C.
58 - Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study
979 - Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)
979 - Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)
Pastre, V. G.
Pasupuleti, A. K.
Pasvolsky, O.
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
Pasvolsky, O.
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Paszkiewicz-Kozik, E.
1738 - Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
4405 - Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study
4405 - Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study
Paszkiewicz-Kozik, E.
578 - Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma
3025 - Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study
3025 - Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study
Patah, P. P.
Patalon, T.
Patan, S.
Patel, A. A.
447 - Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
1425 - Clinical and Molecular Characterization of TP53-Mutant Acute Lymphoblastic Leukemia
1432 - Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1452 - Targeting Menin in T-Lineage Acute Lymphoblastic Leukemia
1487 - Leukemia Physician’s Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia
1489 - Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
1787 - Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors
2423 - Association of Neighborhood Crime with AML Molecular Subtypes and Survival
2800 - Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis
2801 - Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3794 - Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
1425 - Clinical and Molecular Characterization of TP53-Mutant Acute Lymphoblastic Leukemia
1432 - Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1452 - Targeting Menin in T-Lineage Acute Lymphoblastic Leukemia
1487 - Leukemia Physician’s Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia
1489 - Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
1787 - Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors
2423 - Association of Neighborhood Crime with AML Molecular Subtypes and Survival
2800 - Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis
2801 - Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3794 - Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
Patel, A. R.
Patel, A.
Patel, A. P.
1106 - IHP-102 Reduces Hypoxia-Induced Pain Behaviors in Townes SCD Mice
2216 - Proposed Use of the Microfluidic Impedance Red Cell Assay (MIRCA) to Identify Individuals with Sickle Cell Disease in Need of Second Line Therapies
2492 - Long-Term Therapy with GBT021601 and Moderate Chronic Transfusion Therapy Prevent the Development of Hyperalgesia
2557 - Dapsone in Relapsed/Refractory Adult and Pediatric ITP- a Longitudinal Panel Data Analysis Demonstrates Efficacy, Safety, and Dose Dependent Response Rate Mediated through Drop in Hemoglobin
3896 - A Large Cluster of Parvovirus B19 Aplastic Crisis in Children with Sickle Cell Disease in Atlanta, GA (Dec 2023- July 2024)
4956 - Rheological Comparison of Red Cells from Individuals with SCD Treated with Gene Therapy, Haploidentical Transplantation or Hydroxyurea
2216 - Proposed Use of the Microfluidic Impedance Red Cell Assay (MIRCA) to Identify Individuals with Sickle Cell Disease in Need of Second Line Therapies
2492 - Long-Term Therapy with GBT021601 and Moderate Chronic Transfusion Therapy Prevent the Development of Hyperalgesia
2557 - Dapsone in Relapsed/Refractory Adult and Pediatric ITP- a Longitudinal Panel Data Analysis Demonstrates Efficacy, Safety, and Dose Dependent Response Rate Mediated through Drop in Hemoglobin
3896 - A Large Cluster of Parvovirus B19 Aplastic Crisis in Children with Sickle Cell Disease in Atlanta, GA (Dec 2023- July 2024)
4956 - Rheological Comparison of Red Cells from Individuals with SCD Treated with Gene Therapy, Haploidentical Transplantation or Hydroxyurea
Patel, A.
Patel, B.
Patel, B. A.
32 - Longitudinal Contribution of Distinct Hematopoietic Clones during Marrow Recovery in Immune Aplastic Anemia
34 - T Cell Receptor Clonal Dynamics and Hematopoietic Recovery after Immunotherapy in Severe Aplastic Anemia
439 - Danazol Treatment for Telomere Biology Disorders: Long-Term Results of a Phase I/II Study
1309 - Different Effects of Selective Janus Kinase (JAK) Inhibitors in Murine Bone Marrow Failure
2686 - DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality
2693 - Complement Mediated Immune Activation in HLA Class I Alloimmunized Immune Aplastic Anemia Imputed from Single Cell Analysis of Peripheral Cell Subsets
3711 - Patient Reported Outcomes in Vexas Syndrome
4056 - Single-Cell Multi-Omics Analysis Reveals Dysfunctional Features of the Immune Responses in Vexas Syndrome
4082 - The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate
4094 - T Lymphopenia and Aged Immune System Characterize Immunodeficiency in Adult Patients with Telomere Biology Disorders
1323.1 - Trial in Progress: A Phase I/II Study of the JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
34 - T Cell Receptor Clonal Dynamics and Hematopoietic Recovery after Immunotherapy in Severe Aplastic Anemia
439 - Danazol Treatment for Telomere Biology Disorders: Long-Term Results of a Phase I/II Study
1309 - Different Effects of Selective Janus Kinase (JAK) Inhibitors in Murine Bone Marrow Failure
2686 - DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality
2693 - Complement Mediated Immune Activation in HLA Class I Alloimmunized Immune Aplastic Anemia Imputed from Single Cell Analysis of Peripheral Cell Subsets
3711 - Patient Reported Outcomes in Vexas Syndrome
4056 - Single-Cell Multi-Omics Analysis Reveals Dysfunctional Features of the Immune Responses in Vexas Syndrome
4082 - The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate
4094 - T Lymphopenia and Aged Immune System Characterize Immunodeficiency in Adult Patients with Telomere Biology Disorders
1323.1 - Trial in Progress: A Phase I/II Study of the JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
Patel, B.
Patel, C. M.
Patel, D.
1428 - Epidemiological Trends of Acute Lymphoid Leukemia in Individuals Younger Than 20 Years across 204 Countries and Territories from 1990-2021: A Benchmarking Global Analysis
1494 - Exploring the Burden of Acute Myeloid Leukemia Attributable to Smoking in G20 Countries: A Three-Decade Analysis from the Gbd 2021
3095 - Global Burden and Trend of Burkitt Lymphoma in 38 OECD Countries from 1990-2021: A Benchmarking Global Analysis for the Gbd 2021
1494 - Exploring the Burden of Acute Myeloid Leukemia Attributable to Smoking in G20 Countries: A Three-Decade Analysis from the Gbd 2021
3095 - Global Burden and Trend of Burkitt Lymphoma in 38 OECD Countries from 1990-2021: A Benchmarking Global Analysis for the Gbd 2021
Patel, D. A.
224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial
609 - Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4414 - Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma
609 - Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4414 - Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma
Patel, D. A.
Patel, D.
Patel, E.
Patel, H.
Patel, H. K.
Patel, J.
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
1296 - Title: Clonal Hematopoiesis and Germline Predisposition in High-Risk Leukemia Pedigrees
4556 - Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
1296 - Title: Clonal Hematopoiesis and Germline Predisposition in High-Risk Leukemia Pedigrees
4556 - Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
Patel, J.
1428 - Epidemiological Trends of Acute Lymphoid Leukemia in Individuals Younger Than 20 Years across 204 Countries and Territories from 1990-2021: A Benchmarking Global Analysis
1494 - Exploring the Burden of Acute Myeloid Leukemia Attributable to Smoking in G20 Countries: A Three-Decade Analysis from the Gbd 2021
1494 - Exploring the Burden of Acute Myeloid Leukemia Attributable to Smoking in G20 Countries: A Three-Decade Analysis from the Gbd 2021
Patel, K.
Patel, K.
Patel, K.
Patel, K. P.
1680 - Survival Outcomes and Genetic Assessment in Patients with Dual Diagnoses of B-Cell and T-Cell Lymphomas
1807 - Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases
2853 - Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
4224 - Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
1807 - Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases
2853 - Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
4224 - Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
Patel, K. P.
1456 - Age-Related Prognoses of Genetic Subtypes in B-Cell Acute Lymphoblastic Leukemia/Lymphoma (B-ALL): Insights from a Decade of National Data
1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)
1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)
Patel, K.
788 - Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia
3644 - Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
3644 - Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
Patel, K. K.
611 - Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data
767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1031 - Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
3388 - Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
3764 - Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1031 - Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
3388 - Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
3764 - Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
Patel, K.
470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
3111 - Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
3111 - Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
Patel, K.
748 - Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
2088 - Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies
4497 - Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy
5097 - Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
2088 - Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies
4497 - Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy
5097 - Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
Patel, M.
Patel, M.
Patel, M. H.
Patel, M. N.
Patel, M.
141 - Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study
4006 - Pharmacodynamic Activity of Recombinant ADAMTS13 Versus Plasma-Based Therapies in Congenital Thrombotic Thrombocytopenic Purpura: Interim Results of a Phase 3 Randomized, Controlled, Open-Label Study
4006 - Pharmacodynamic Activity of Recombinant ADAMTS13 Versus Plasma-Based Therapies in Congenital Thrombotic Thrombocytopenic Purpura: Interim Results of a Phase 3 Randomized, Controlled, Open-Label Study
Patel, N.
Patel, N.
2821 - Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
3148 - 5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results
3148 - 5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results
Patel, N.
1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
2005 - Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting
3390 - Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2–4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
2005 - Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting
3390 - Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2–4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Patel, P.
Patel, P. C.
Patel, P.
Patel, P. A.
1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
1841 - Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (mIDH1) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
5196 - Indirect Treatment Comparison of Ivosidenib and Other Therapies in Patients with Newly Diagnosed Acute Myeloid Leukemia
1845.1 - Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)
1841 - Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (mIDH1) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
5196 - Indirect Treatment Comparison of Ivosidenib and Other Therapies in Patients with Newly Diagnosed Acute Myeloid Leukemia
1845.1 - Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)
Patel, P.
283 - National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma
1993 - Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma
5144 - First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma
1993 - Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma
5144 - First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma
Patel, P.
Patel, R.
2132 - Efficacy of Recombinant Human Erythropoietin in Enhancing Erythroid Hematopoietic Recovery after Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis
2443 - Unveiling Regional Disparities in Cancer Care - Analysis of the Geographical Journey and Relocation Patterns of Hematology/Oncology Fellowship Graduates
2443 - Unveiling Regional Disparities in Cancer Care - Analysis of the Geographical Journey and Relocation Patterns of Hematology/Oncology Fellowship Graduates
Patel, R. M.
Patel, R.
Patel, R. R.
Patel, R. P.
4 - Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate
500 - CD5 Elimination Enhances CART Cell Proliferation through JAK-STAT Activation
504 - Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies
4848 - Evaluating Efficacy and Safety of Rapid-Manufactured CD5KO CART5 Cells in Preclinical Models of T Cell Malignancies
500 - CD5 Elimination Enhances CART Cell Proliferation through JAK-STAT Activation
504 - Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies
4848 - Evaluating Efficacy and Safety of Rapid-Manufactured CD5KO CART5 Cells in Preclinical Models of T Cell Malignancies
Patel, R.
Patel, S.
Patel, S. S.
472 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
2134.1 - Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207
694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
2134.1 - Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207
Patel, S. N.
2392 - Real-World Talquetamab Utilization Patterns and Dose Schedules in the United States: An Analysis Using Claims Data
3786 - Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research
5157 - Patient Characteristics, Treatment Patterns and Early Outcomes of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study
5170b - Real-World Step-up Dosing Practice for Patients Who Initiated Talquetamab in US Hospitals: An Analysis of the All-Payer US Hospital Administrative Premier Healthcare Database
3786 - Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research
5157 - Patient Characteristics, Treatment Patterns and Early Outcomes of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study
5170b - Real-World Step-up Dosing Practice for Patients Who Initiated Talquetamab in US Hospitals: An Analysis of the All-Payer US Hospital Administrative Premier Healthcare Database
Patel, S. R.
Patel, S.
Patel, S. B.
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Patel, S.
Patel, S. A.
1546 - p53 Immunohistochemistry As a High-Specificity Biomarker to Predict Allelic State and Overall Survival in Myelodysplastic Syndrome or Acute Myeloid Leukemia with Mutated TP53
1553 - Characteristics and Clinical Outcomes of Patients with Myeloid Malignancies and Cohesin Mutations
2125 - Association between Malnutrition and Inpatient Mortality in Hematopoietic Stem Cell Transplant (HSCT) Population: A Nationwide Inpatient Sample (NIS) Database Analysis
2418 - Treatment Patterns and Survival Outcomes for Very Elderly Patients with Acute Myeloid Leukemia: A National Cancer Database Study
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
1553 - Characteristics and Clinical Outcomes of Patients with Myeloid Malignancies and Cohesin Mutations
2125 - Association between Malnutrition and Inpatient Mortality in Hematopoietic Stem Cell Transplant (HSCT) Population: A Nationwide Inpatient Sample (NIS) Database Analysis
2418 - Treatment Patterns and Survival Outcomes for Very Elderly Patients with Acute Myeloid Leukemia: A National Cancer Database Study
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
Patel, S.
Patel, S.
Patel, S. B.
39 - MCL1 Promotes Fatty Acid β-Oxidation in Therapy-Resistant AML through Cytoplasmic Sequestration of the Transcriptional Repressor IRF2BP2
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
2648 - Mitochondrial Metabolism Underlies Developmental Programming of Hematopoietic Stem Cell Function By Prenatal Folate
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
2648 - Mitochondrial Metabolism Underlies Developmental Programming of Hematopoietic Stem Cell Function By Prenatal Folate
Patel, T. H.
254 - Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)
4713 - Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
4713 - Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
Patel, U.
Patel, U.
Patel, V. M.
Patel, V.
Patel, V.
Patel Wrench, B.
Patel-Shah, B.
1825 - Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)
4591 - Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
4591 - Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
Patell, R.
16 - Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)
701 - Glucagon-like Peptide 1 Receptor Agonists Reduce the Risk of Venous Thromboembolism in Patients with Diabetes Irrespective of Obesity: A Propensity Score-Matched Multicenter Database Analysis
816 - Comparison of Anticoagulants in the Prevention of Arterial Thromboembolism in Patients with Cancer and Venous Thromboembolism: A Population-Based Cohort Study
1247 - Anticoagulation and Major Bleeding or Recurrent Thrombosis in Patients with Isolated Cancer-Associated Splanchnic Vein Thrombosis: A Multi-Center Cohort Study
2625 - Peri-Procedural Anticoagulation Interruption in Acute Cancer Associated Thrombosis
3695 - Comparing Extended Vs. Standard Postoperative Thromboprophylaxis in Patients Undergoing Abdominopelvic Surgery for Malignancy; A Population-Based Cohort Study
701 - Glucagon-like Peptide 1 Receptor Agonists Reduce the Risk of Venous Thromboembolism in Patients with Diabetes Irrespective of Obesity: A Propensity Score-Matched Multicenter Database Analysis
816 - Comparison of Anticoagulants in the Prevention of Arterial Thromboembolism in Patients with Cancer and Venous Thromboembolism: A Population-Based Cohort Study
1247 - Anticoagulation and Major Bleeding or Recurrent Thrombosis in Patients with Isolated Cancer-Associated Splanchnic Vein Thrombosis: A Multi-Center Cohort Study
2625 - Peri-Procedural Anticoagulation Interruption in Acute Cancer Associated Thrombosis
3695 - Comparing Extended Vs. Standard Postoperative Thromboprophylaxis in Patients Undergoing Abdominopelvic Surgery for Malignancy; A Population-Based Cohort Study
Paterno, G.
Paterson, H.
Pathak, H. B.
Pathak, K. V.
Pathak, P.
Pathiraja, K.
1738 - Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
3046 - Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update
3046 - Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update
Patil, K. A.
Patil, K.
Patil, P.
Patil, S.
Patil, S. S.
303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
Patino Escobar, B.
Patino-Escobar, B.
Patiño-Escobar, B.
Patkar, N.
852 - Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
2953 - Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
2953 - Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)
Patkar, O.
Patki, A.
Patkowska, E.
848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results
970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results
Patnaik, D.
3187 - Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison
3804 - Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States
3815 - Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis
3804 - Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States
3815 - Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis
Patnaik, M. M.
244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
440 - Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1326 - Natural History and Predictors of Survival in Adult Patients with Telomere Biology Disorders
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
1827 - Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform
2667 - A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations
2686 - DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality
2771 - Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2869 - Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients
3169 - Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
3197 - Targeting Aberrant DLK1 Re-Expression in ASXL1-Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4586 - PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
- Moderator Introduction
440 - Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1326 - Natural History and Predictors of Survival in Adult Patients with Telomere Biology Disorders
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
1827 - Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform
2667 - A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations
2686 - DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality
2771 - Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2869 - Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients
3169 - Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
3197 - Targeting Aberrant DLK1 Re-Expression in ASXL1-Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4586 - PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
- Moderator Introduction
Patos, P.
Patou, G.
805 - ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis
3978 - Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset
3980 - Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset
3981 - A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding
3978 - Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset
3980 - Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset
3981 - A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding
Patrakova, E.
Patriarca, A.
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
Patriarca, F.
Patrick, B.
Patriquin, C.
2692 - Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial
5085 - Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada
5085 - Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada
Patriquin, C.
Patrone, M.
Patrus, G.
Patsialos, I.
Patsilevas, T.
Patsoukis, N.
Patten, P. E.
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
4382 - Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment
3257.1 - CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL
4382 - Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment
3257.1 - CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL
Patterson, C.
Patterson, C. J.
743 - Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
Patterson, F.
Patterson, M.
3101 - Durability of Complete Responses in Patients from the ECHELON-3 Study
4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4489 - Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4489 - Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
Patterson, P.
Patterson, R.
Patterson, S. D.
Patterson, T.
Patterson, V.
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Patti, C.
1626 - High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma
1872 - Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
1872 - Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
Patti, C.
578 - Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma
1580 - Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients
3046 - Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update
1580 - Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients
3046 - Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update
Patwardhan, A. A.
Patwari, A.
256 - Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
287 - Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy
3781 - Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
287 - Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy
3781 - Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
Patwari, P.
141 - Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study
4002 - Mutation Analysis of the ADAMTS13 Gene in Patients with Congenital Thrombotic Thrombocytopenic Purpura from the rADAMTS13 Phase 3 Study
4006 - Pharmacodynamic Activity of Recombinant ADAMTS13 Versus Plasma-Based Therapies in Congenital Thrombotic Thrombocytopenic Purpura: Interim Results of a Phase 3 Randomized, Controlled, Open-Label Study
4002 - Mutation Analysis of the ADAMTS13 Gene in Patients with Congenital Thrombotic Thrombocytopenic Purpura from the rADAMTS13 Phase 3 Study
4006 - Pharmacodynamic Activity of Recombinant ADAMTS13 Versus Plasma-Based Therapies in Congenital Thrombotic Thrombocytopenic Purpura: Interim Results of a Phase 3 Randomized, Controlled, Open-Label Study
Paudel, N.
Paul, B.
1929 - Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study
1964 - Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions
1965 - Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study
2009 - A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment
2287 - Supportive Care Utilization in Patients with Multiple Myeloma—a Single Center Retrospective Study
2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy
3317 - Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis
3388 - Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
3769 - Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center
4702 - Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
4720 - Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution
4751 - Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy
5040 - Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns
5170d - Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients
5170e - Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents
1964 - Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions
1965 - Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study
2009 - A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment
2287 - Supportive Care Utilization in Patients with Multiple Myeloma—a Single Center Retrospective Study
2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy
3317 - Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis
3388 - Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
3769 - Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center
4702 - Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
4720 - Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution
4751 - Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy
5040 - Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns
5170d - Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients
5170e - Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents
Paul, D.
Paul, M. A.
402 - Pediatric RISE: Development of a Poverty-Targeted Cash Support Intervention for Pediatric Cancer
3649 - Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
5130 - Food Insecurity and Cardiovascular Risk Among Survivors of Pediatric Hematologic Malignancies
3649 - Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
5130 - Food Insecurity and Cardiovascular Risk Among Survivors of Pediatric Hematologic Malignancies
Paul Roc, N.
Paul, S.
Paul, S.
Paul, S.
Paúl Vidaller, P.
Paul-Prasanth, B.
Paule, R.
Paulino, D.
Paulli, M.
1639 - Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi
3020 - Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study
4400 - Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?
3020 - Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study
4400 - Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?
Paulose, J.
Paulsen, S.
Paulson, K.
Paulson, R.
Paulsson, K.
Paulus, G.
Paulus, J.
2410 - Real-World Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting
3094 - Trends in Real-World Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated in the US Community Oncology Setting Pre- and Post-CAR-T Approvals
3094 - Trends in Real-World Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated in the US Community Oncology Setting Pre- and Post-CAR-T Approvals
Paun, B.
Paushkin, S.
Pavalagantharajah, S.
Pavan, A. R.
Pavasovic, V.
Paviglianiti, A.
Pavlatos, E.
Pavletic, S. Z.
Pavlic, J.
Pavlicek, P.
1999 - A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma
2378 - Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets – Analysis of the Czech Myeloma Group
2378 - Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets – Analysis of the Czech Myeloma Group
Pavlova, A.
382 - Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies
694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
3332 - The Impact of Circulating Plasma Cells on Overall Survival (OS) in Patients with Newly Diagnosed Multiple Myeloma (MM) - Results of a Multicenter Study
694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
3332 - The Impact of Circulating Plasma Cells on Overall Survival (OS) in Patients with Newly Diagnosed Multiple Myeloma (MM) - Results of a Multicenter Study
Pavlovsky, C.
3148 - 5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results
3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
4526 - Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study
3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
4526 - Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study
Pavlu, J.
2190 - Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
2497 - Combined Red Cell and Plasma Exchange Is Associated with Reduced Mortality of Fat Embolism Syndrome in Sickle Cell Disease
3163 - BCR::ABL1 transcript Type Does Not Impact Allogeneic Stem Cell Transplant Outcome in Chronic Myeloid Leukaemia
4892.1 - Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST): A Multi-Center Randomized Double-Blinded Placebo-Controlled Phase IIa Trial
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
2497 - Combined Red Cell and Plasma Exchange Is Associated with Reduced Mortality of Fat Embolism Syndrome in Sickle Cell Disease
3163 - BCR::ABL1 transcript Type Does Not Impact Allogeneic Stem Cell Transplant Outcome in Chronic Myeloid Leukaemia
4892.1 - Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST): A Multi-Center Randomized Double-Blinded Placebo-Controlled Phase IIa Trial
Pavone, V.
339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
Pavoni, C.
2106 - Early Mixed Lymphoid Chimerism in Acute Myeloid Leukemia Patients Undergoing Allogeneic Transplantation after a Myeloablative Busulfan-Based Conditioning Regimen
2192 - Effective Cytoreductive Treatment before Allogeneic Hematopoietic Stem Cell Transplantation May Improve the Outcome of Patients with Blast Phase Myelofibrosis
3114 - GMALL B ALL/NHL 2002 Protocol Yields High Response Rates and Durable Responses in High-Grade B Cell Lymphoma: A Retrospective, Single-Center Study
2192 - Effective Cytoreductive Treatment before Allogeneic Hematopoietic Stem Cell Transplantation May Improve the Outcome of Patients with Blast Phase Myelofibrosis
3114 - GMALL B ALL/NHL 2002 Protocol Yields High Response Rates and Durable Responses in High-Grade B Cell Lymphoma: A Retrospective, Single-Center Study
Pavy, M.
Pawar, A. S.
Pawar, S. G.
Pawelko, A.
Pawlitzky, I.
Pawlowski, C.
Pawlyn, C.
385 - Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma – an Economic Evaluation of the Fitness Trial
673 - IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
771 - Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients
1023 - Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
1913 - The Complex Psychological Effects and Perspectives of Patients on Diagnosis, Monitoring, and Future Treatments for MGUS and Smoldering Myeloma: A Mixed Methods Study
1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
1987 - Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients – Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial
3284 - IMiDs and Celmods Enhance Antigen Presentation Via MHC Class 1 – a Potential Novel Immunostimulatory Effect
3375 - MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation
4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
5150 - A National UK Survey of Multiple Myeloma Patient Led Research Priorities: Embedding PROMs, Patient Characteristics and Patient Perspectives
673 - IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
771 - Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients
1023 - Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
1913 - The Complex Psychological Effects and Perspectives of Patients on Diagnosis, Monitoring, and Future Treatments for MGUS and Smoldering Myeloma: A Mixed Methods Study
1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
1987 - Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients – Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial
3284 - IMiDs and Celmods Enhance Antigen Presentation Via MHC Class 1 – a Potential Novel Immunostimulatory Effect
3375 - MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation
4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
5150 - A National UK Survey of Multiple Myeloma Patient Led Research Priorities: Embedding PROMs, Patient Characteristics and Patient Perspectives
Payán-Pernía, S.
Payne, C.
Payne, C.
Payne, E.
Payne, J. N.
Payne, S.
Payne, S.
Payson, E.
Pazos, II, M.
Peachey, A.
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
Peacock, K.
Pearse, R.
1886 - CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma
1930 - Prognostic Factors for Survival in Multiple Myeloma Patients That Receive Bispecific Antibodies: Does Relative Dose Intensity Matters?
1936 - Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events
1942 - Evaluating the Kinetics of Absolute Lymphocyte Counts Following Bispecific T-Cell Engager Therapy to Predict Clinical Outcomes in Relapsed/Refractory Multiple Myeloma
1930 - Prognostic Factors for Survival in Multiple Myeloma Patients That Receive Bispecific Antibodies: Does Relative Dose Intensity Matters?
1936 - Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events
1942 - Evaluating the Kinetics of Absolute Lymphocyte Counts Following Bispecific T-Cell Engager Therapy to Predict Clinical Outcomes in Relapsed/Refractory Multiple Myeloma
Pearson, D.
67 - Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update
149 - Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform
149 - Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform
Pearson, L. K.
1553 - Characteristics and Clinical Outcomes of Patients with Myeloid Malignancies and Cohesin Mutations
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4625 - Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4625 - Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
Pecarskie, A.
Peccatori, J.
Pechetty, P.
Pechlivanis, N.
Pecker, L. H.
Peckner, R.
Pecora, A. L.
1946 - Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)
3316 - Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
4295 - Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)
4367 - Establishing Lymphoma Type-Specific Cytokine Signatures Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)
3316 - Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
4295 - Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)
4367 - Establishing Lymphoma Type-Specific Cytokine Signatures Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)
Peddinti, R.
Pedersen, J. B.
Pedersen, L. M.
Pedersen, L. B.
Pedersen, M. B.
Pedersen, R. S.
650 - Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group
1988 - Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21
1988 - Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21
Pedersen, S.
Pederson, L. D.
110 - Representation of Minorities in Therapeutic Clinical Trials – a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)
1972 - Initial Results from the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2393 - Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
1972 - Initial Results from the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2393 - Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
Pednekar, P.
Pedone, G. L.
Pedone, G. L.
Pedraza, A.
Pedrote Amador, B.
Pedrote, B.
Peek, M. E.
Peffault De Latour, R.
33 - Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race Trial
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
596 - Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study
925 - The Influence of HLA Matching of the Winning and Losing Units in Relapse of Patients Receiving Double Cord Blood Transplantation for Acute Leukemia or Myelodysplastic Syndrome
1314 - Recursive Partitioning As a Tool for Differential Diagnosis between Acquired and Inherited Bone Marrow Failure Syndromes (BMF)
2329 - Incidence, Time to Diagnosis, and Therapeutic Landscape of Aplastic Anemia: Results from a Large United States Claims Database
3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)
3559 - Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
3706 - The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry: Highlights of the Data from the First Three Years
4075 - Upfront HSCT with an Alemtuzumab Based Conditioning Regimen in Children with Acquired Aplastic Anemia: A Retrospective Study from the SFGM-TC
4079 - Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials
4087 - The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial
4859 - Up-Front Matched Unrelated Donor Transplantation in Pediatric Patients with Idiopathic Aplastic Anemia: A Phase II Feasibility Study, on Behalf of Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and French Reference National Center of Severe Aplastic Anemia
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
5012 - Incremental Effectiveness of Iptacopan Compared with C5 Inhibitors in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from a Modelling Analysis
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
596 - Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study
925 - The Influence of HLA Matching of the Winning and Losing Units in Relapse of Patients Receiving Double Cord Blood Transplantation for Acute Leukemia or Myelodysplastic Syndrome
1314 - Recursive Partitioning As a Tool for Differential Diagnosis between Acquired and Inherited Bone Marrow Failure Syndromes (BMF)
2329 - Incidence, Time to Diagnosis, and Therapeutic Landscape of Aplastic Anemia: Results from a Large United States Claims Database
3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)
3559 - Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
3706 - The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry: Highlights of the Data from the First Three Years
4075 - Upfront HSCT with an Alemtuzumab Based Conditioning Regimen in Children with Acquired Aplastic Anemia: A Retrospective Study from the SFGM-TC
4079 - Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials
4087 - The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial
4859 - Up-Front Matched Unrelated Donor Transplantation in Pediatric Patients with Idiopathic Aplastic Anemia: A Phase II Feasibility Study, on Behalf of Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and French Reference National Center of Severe Aplastic Anemia
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
5012 - Incremental Effectiveness of Iptacopan Compared with C5 Inhibitors in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from a Modelling Analysis
Peffault de Latour, R.
1321 - Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center
1329 - Hematological Landscape of Adult Patients with Diamond-Blackfan Anaemia Syndrome (DBAS): Results from the French DBA Cohort
3457 - SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post HLA Mismatched Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Reset-02 First-in-Human Phase I/II
3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4080 - High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study
LBA-5 - Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities
1329 - Hematological Landscape of Adult Patients with Diamond-Blackfan Anaemia Syndrome (DBAS): Results from the French DBA Cohort
3457 - SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post HLA Mismatched Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Reset-02 First-in-Human Phase I/II
3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4080 - High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study
LBA-5 - Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities
Pegoraro, E.
Pegoraro, F.
3908 - Prognostic Value of BRAFV600E in Peripheral Blood of Children with Langerhans Cell Histiocytosis: A Multicenter Project of the European Consortium for Histiocytosis
3909 - Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)
3909 - Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)
Pegtel, D. M.
Pei, C.
Pei, R.
Pei, S.
38 - The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia
843 - The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
3400 - Combined Single-Cell and Spatial Transcriptomics Reveals the Cellular Landscape of Bronchiolitis Obliterans Syndrome in Chronic Graft-Versus-Host Disease Mouse Model
843 - The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
3400 - Combined Single-Cell and Spatial Transcriptomics Reveals the Cellular Landscape of Bronchiolitis Obliterans Syndrome in Chronic Graft-Versus-Host Disease Mouse Model
Pei, X.
Pei, X.
Peifer, M.
Peipp, M.
636 - CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL
914 - A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies
4173 - Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia
914 - A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies
4173 - Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia
Peiser, L.
72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study
3410 - Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study
3410 - Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study
Pelaez, G. D.
Pelagatti, L.
4656 - Single Cell Transcriptomics on Bone Marrow Biopsies Unveils Peculiar Bone Microenvironment Cell Subtypes and Highlights Alterations Correlated with High-Risk Features in Precursor Monoclonal Gammopathies and Multiple Myeloma Patients
4660 - Bovine Herpes Virus Type 1 Oncolytic Therapy Elicits Direct Cytotoxic Effects and Immune Microenvironment Reshaping in Multiple Myeloma
4660 - Bovine Herpes Virus Type 1 Oncolytic Therapy Elicits Direct Cytotoxic Effects and Immune Microenvironment Reshaping in Multiple Myeloma
Pelcovits, A.
473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
1614 - Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma
1644 - Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study
2273 - Early Experience with Mosunetuzumab and Managing Cytokine Release Syndrome: Results of a Single Center Retrospective
2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
1614 - Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma
1644 - Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study
2273 - Early Experience with Mosunetuzumab and Managing Cytokine Release Syndrome: Results of a Single Center Retrospective
2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
Peled, J. U.
259 - Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical Gvhd Models
501 - Dual-Vector-Transduction with Single-Step Magnetic Selection (Zip-sort) Increases Transgenic Payloads to Enhance CAR T Cell Activity
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
3498 - Disparities in Microbiota Diversity Impacting Non-European Recipients of 8/8 HLA-Matched Unrelated Donor Transplantation
4943 - Dietary Sucrose Exacerbates Antibiotic-Induced Microbiome Injury in Allo-HCT
501 - Dual-Vector-Transduction with Single-Step Magnetic Selection (Zip-sort) Increases Transgenic Payloads to Enhance CAR T Cell Activity
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
3498 - Disparities in Microbiota Diversity Impacting Non-European Recipients of 8/8 HLA-Matched Unrelated Donor Transplantation
4943 - Dietary Sucrose Exacerbates Antibiotic-Induced Microbiome Injury in Allo-HCT
Peled, S.
Peleteiro Raindo, A.
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Pelicci, P. G.
1388 - Role of the Interferon Alpha Inducible Protein 6 (IFI6) in Establishing Chemoresistance in Acute Myeloid Leukemia
1541 - Genomic Landscape and Clonal Hematopoiesis Dynamics in Patients with Ovarian Cancer during PARP Inhibitors Treatment: Preliminary Results of a Prospective Longitudinal Study
1541 - Genomic Landscape and Clonal Hematopoiesis Dynamics in Patients with Ovarian Cancer during PARP Inhibitors Treatment: Preliminary Results of a Prospective Longitudinal Study
Peliconi, J.
Pelissier, L.
Pelizzari, A. M.
Pellagatti, A.
Pelland-Marcotte, M. C.
298 - Clinical Outcomes of Neonatal Central Line-Related Thrombosis: A Multicentric Retrospective Cohort Study
1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2623 - Clinical Significance of Incidental Central Venous Catheter-Related Thrombosis in Children Previously Treated for Cancer
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
3697 - Impact of Obesity on Anticoagulation Dosing and Clinical Outcomes in Pediatric Patients with Venous Thrombo-Embolism
1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2623 - Clinical Significance of Incidental Central Venous Catheter-Related Thrombosis in Children Previously Treated for Cancer
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
3697 - Impact of Obesity on Anticoagulation Dosing and Clinical Outcomes in Pediatric Patients with Venous Thrombo-Embolism
Pellat-Deceunynck, C.
Pellé, O.
Pellegrini, C.
Pellegrini, D.
Pellegrini, V.
Pellegrino, C.
Pellegrino, R. M.
Pellerin, A.
Pelletier, A.
Pelletier, M.
Pelletier, M.
Pelletier, O.
Pelletier, S. G.
Pellier, I.
1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
Pelligra, C. G.
2346 - Estimation of Health State Utility Values for Patients Undergoing First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the HD21 Trial
3216 - Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study
3857 - Luspatercept Improves Fatigue-Related Quality of Life through 5 Years of Treatment in Non-Transfusion Dependent Beta-Thalassemia
3216 - Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study
3857 - Luspatercept Improves Fatigue-Related Quality of Life through 5 Years of Treatment in Non-Transfusion Dependent Beta-Thalassemia
Pellon, M.
Peloso, A.
Pelosof, L.
Peltier, S.
Peltonen, K.
Pemmaraju, N.
56 - Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
216 - Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
446 - Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine
734 - A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
735 - Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations
999 - A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib
1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1511 - Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up
1515 - Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
1760 - Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis
1800 - Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations
1807 - Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1842 - Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2749 - Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
2851 - Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease
2853 - Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML
2861 - Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
2901 - A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
3136 - Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study
3142 - Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
3813 - Real-World Treatment Patterns and Blood Count Control in Patients with Polycythemia Vera Who Switched from Hydroxyurea to Ruxolitinib
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4207 - Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL
4251 - Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4559 - Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
4265.1 - Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
- BPDCN State of the Art
216 - Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
446 - Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine
734 - A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
735 - Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations
999 - A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib
1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1511 - Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up
1515 - Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
1760 - Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis
1800 - Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations
1807 - Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1842 - Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2749 - Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
2851 - Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease
2853 - Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML
2861 - Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
2901 - A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
3136 - Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study
3142 - Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
3813 - Real-World Treatment Patterns and Blood Count Control in Patients with Polycythemia Vera Who Switched from Hydroxyurea to Ruxolitinib
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4207 - Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL
4251 - Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4559 - Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
4265.1 - Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
- BPDCN State of the Art
Pemovska, T.
Peña, C.
983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study
3774 - Smoldering Multiple Myeloma in Latin America- Risk Stratification
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study
3774 - Smoldering Multiple Myeloma in Latin America- Risk Stratification
Peña, F.
598 - HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
2105 - Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
3531 - Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4947 - Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies
2105 - Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
3531 - Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4947 - Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies
Peña, I.
Peña, M.
2105 - Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4947 - Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4947 - Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies
Peña, S.
Peña-Martínez, P.
Penaloza, A.
Penaloza, A.
Peñalver, F. J.
Penarrubia Ponce, M. J.
Peñarrubia-Ponce, M.
Pence, P.
Pender, A.
Pender, B.
Pendhari, J.
Peng, B.
Peng, C. T.
Peng, C. Y.
Peng, F.
Peng, H.
1485 - Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
1505 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
1904 - The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
1937 - Identification of Risk Factors for Myeloma Progression in African American Patients
2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia
3230 - Aberrant c-AMP Signalling in Richter Syndrome Revealed By Single-Cell Transcriptome and 3D Chromatin Analysis
3411 - IL-2-Inducible T Cell Kinase Deficiency Enables Development of Sustainable Chimeric Antigen Receptor T Cell Therapy
4279 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia
4417 - Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd
1505 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
1904 - The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
1937 - Identification of Risk Factors for Myeloma Progression in African American Patients
2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia
3230 - Aberrant c-AMP Signalling in Richter Syndrome Revealed By Single-Cell Transcriptome and 3D Chromatin Analysis
3411 - IL-2-Inducible T Cell Kinase Deficiency Enables Development of Sustainable Chimeric Antigen Receptor T Cell Therapy
4279 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia
4417 - Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd
Peng, H.
Peng, H.
Peng, J.
Peng, J.
Peng, J.
Peng, L.
998 - Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
Peng, Q.
Peng, S.
Peng, S.
169 - Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease
1395 - Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)
4142 - BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53
1395 - Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)
4142 - BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53
Peng, Y.
1950 - Proliferative CD8 T-Cells: A Novel Immune Microenvironmental Determinant of Outcomes in Multiple Myeloma with Translocation (4;14)
3602 - Machine Learning Classification of Spatial Patterns of Malignant Cells Reveals Implications in Prognosis and Tumor Microenvironment Composition in Lymphoma
3602 - Machine Learning Classification of Spatial Patterns of Malignant Cells Reveals Implications in Prognosis and Tumor Microenvironment Composition in Lymphoma
Peng, Y. C.
Peng, Z.
Peng, Z.
1635 - Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
3119 - Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma
4450 - Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study
3119 - Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma
4450 - Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study
Peniket, A.
749 - Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Pennella, C. L.
Pennese, E.
Pennings, E. R.
Pennington, S.
2305 - Voxelotor Therapy Reduces Whole Blood Adhesion to VCAM-1 and P-Selectin, and Shows Modest Improvements in Self-Reported Pain in a Real-World Clinical Setting in a Multi-Center Retrospective Analysis
3875 - Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)
3875 - Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)
Penny, S.
Penta de Vera d'aragona, R.
Penter, L.
44 - Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients
926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations
1529 - Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes
926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations
1529 - Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes
Penther, D.
226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network
227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
4353 - Clonal Dominance in Follicular Lymphoma: A Predictor of Poor Prognosis and Histological Transformation
227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
4353 - Clonal Dominance in Follicular Lymphoma: A Predictor of Poor Prognosis and Histological Transformation
Penuel, E.
1645 - Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
Penuel, E.
989 - A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
Penza, S.
Penzo, M.
Peplinski, J. H.
638 - Dysregulation of Developmental Transcription Factors in Acute Myeloid Leukemia Predicts Poor Outcome and Impacts Adaptive Immune Pathway Genes
849 - Comprehensive Characterization of Rare Recurrent Mutations in Pediatric AML
1555 - Contrasting Clinical Implications of NRAS Vs. KRAS Mutations in AML – Only KRAS Mutations Are Associated with Adverse Outcome
1562 - Haplo-Insufficiency of RAS Genes Is the Determinant of Outcome in AML
2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A
2925 - The AML HOX-Ome: The Landscape of Developmental Transcription Factors across Pediatric Acute Myeloid Leukemia
3413 - Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia
849 - Comprehensive Characterization of Rare Recurrent Mutations in Pediatric AML
1555 - Contrasting Clinical Implications of NRAS Vs. KRAS Mutations in AML – Only KRAS Mutations Are Associated with Adverse Outcome
1562 - Haplo-Insufficiency of RAS Genes Is the Determinant of Outcome in AML
2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A
2925 - The AML HOX-Ome: The Landscape of Developmental Transcription Factors across Pediatric Acute Myeloid Leukemia
3413 - Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia
Pepperell, D.
303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
Peprah, E.
Peragine, N.
Perales, M. A.
68 - Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
267 - Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies
608 - Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma
686 - Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies
781 - Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center
912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy
2068 - NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2367 - Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
3128 - A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort
3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma
4503 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium
4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease
4943 - Dietary Sucrose Exacerbates Antibiotic-Induced Microbiome Injury in Allo-HCT
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
- When to Use Stem Cell Transplantation for Classical Hodgkin Lymphoma
267 - Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies
608 - Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma
686 - Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies
781 - Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center
912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy
2068 - NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2367 - Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
3128 - A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort
3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma
4503 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium
4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease
4943 - Dietary Sucrose Exacerbates Antibiotic-Induced Microbiome Injury in Allo-HCT
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
- When to Use Stem Cell Transplantation for Classical Hodgkin Lymphoma
Peralta, E.
3474 - Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells
4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy
4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy
Peralta, G.
Peralta, N.
Peralta, R.
Peranteau, W.
Perantonaki, A. M.
Perbellini, O.
Percier, C.
Percival, M. E. M.
6 - Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study
265 - CLAG-M or FLAG-Ida Followed Immediately By Allogeneic Hematopoietic Cell Transplantation for Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm
733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
1530 - 4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)
4209 - Extended Follow-up of Dose-Adjusted EPOCH (DA-EPOCH) Plus Inotuzumab Ozogamicin (InO) in Adults with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Safe and Effective Salvage Therapy
4288 - Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms
265 - CLAG-M or FLAG-Ida Followed Immediately By Allogeneic Hematopoietic Cell Transplantation for Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm
733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
1530 - 4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)
4209 - Extended Follow-up of Dose-Adjusted EPOCH (DA-EPOCH) Plus Inotuzumab Ozogamicin (InO) in Adults with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Safe and Effective Salvage Therapy
4288 - Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms
Perdomo, M.
Perdue, N.
Pereira, A.
Pereira, A.
Pereira, G.
Pereira, J.
983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
4452 - Extranodal NK/T-Cell Lymphoma in Latin America: A Retrospective Multinational Analysis of Clinical Features, Therapeutic Approaches and Outcomes from the Latin American Group of Lymphoproliferative Disorders (GELL)
4458 - Outcomes and Toxicity Profile in Elderly and Very-Elderly Diffuse Large B-Cell Lymphoma Patients: A Real-World and Comparative Study Involving Three Different Dose-Modulated Anthracycline-Based Immunochemotherapy Regimens in LATAM
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
4452 - Extranodal NK/T-Cell Lymphoma in Latin America: A Retrospective Multinational Analysis of Clinical Features, Therapeutic Approaches and Outcomes from the Latin American Group of Lymphoproliferative Disorders (GELL)
4458 - Outcomes and Toxicity Profile in Elderly and Very-Elderly Diffuse Large B-Cell Lymphoma Patients: A Real-World and Comparative Study Involving Three Different Dose-Modulated Anthracycline-Based Immunochemotherapy Regimens in LATAM
Pereira, R. M.
Pereira-Martins, D. A.
Pereira-Martins, D. A.
944 - Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress
1350 - The Oncogenic ΔNp73α Isoform Contributes to Aggressiveness in APL By Leading to ATRA Resistance through NANOG/BMP4 Axis Upregulation
1393 - DGAT1 Inhibition Enhances Metformin-Induced Ferroptosis in AML By Targeting Lipid Metabolism
2752 - Molecular Mechanisms Associated with Autophagy Inhibition to Overcome Resistance to FLT3 Inhibitors
2775 - Plinabulin and Selumetinib Enhance M1 Macrophage Traits and Trigger Cell Death in AML
4321 - The Oncogenic Function of the Intrinsically Disordered Transcriptional Regulator MN1 Depends on the Chaperone DNAJB6b
1350 - The Oncogenic ΔNp73α Isoform Contributes to Aggressiveness in APL By Leading to ATRA Resistance through NANOG/BMP4 Axis Upregulation
1393 - DGAT1 Inhibition Enhances Metformin-Induced Ferroptosis in AML By Targeting Lipid Metabolism
2752 - Molecular Mechanisms Associated with Autophagy Inhibition to Overcome Resistance to FLT3 Inhibitors
2775 - Plinabulin and Selumetinib Enhance M1 Macrophage Traits and Trigger Cell Death in AML
4321 - The Oncogenic Function of the Intrinsically Disordered Transcriptional Regulator MN1 Depends on the Chaperone DNAJB6b
Pereiras, M.
Perelli, L.
Perencsik, R.
Perentesis, J.
Perera Alvarez, M. D.
Perera, A.
559 - Spatial Transcriptomics Characterize Dynamic and Polarized Niche for Embryonic Hematopoiesis at Single-Cell Level
1306 - Characterization of Multicellular Niches Supporting Hematopoietic Stem Cells within Distinct Zones
4042 - Ex Vivo Expansion of Human Hematopoietic Stem Cells By Mimicking Intrinsic and Extrinsic Factors in Adult Bone Marrow
1306 - Characterization of Multicellular Niches Supporting Hematopoietic Stem Cells within Distinct Zones
4042 - Ex Vivo Expansion of Human Hematopoietic Stem Cells By Mimicking Intrinsic and Extrinsic Factors in Adult Bone Marrow
Perera, T.
217 - A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial
2067 - A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)
3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry
2067 - A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)
3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry
Peres Diaz, L.
Peres, L. C.
896 - Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4645 - The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma
5165 - Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4645 - The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma
5165 - Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity
Peretz, C. A.
Pereyra, P.
Perez, A. I.
225 - Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations
4403 - Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?
4403 - Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?
Perez Amill, L.
Perez, A.
Perez, A.
Perez, A.
Perez, A.
3437 - Natural Killer and Gamma Delta T Cells Derived from Engineered Induced Pluripotent Stem Cells Have Potent Preclinical Activity to Treat B Cell-Mediated Autoimmune Diseases
4820 - Leveraging Stage-Specific Promoters to Enhance Immune Cell Engineering in iPSC-Derived Cells for Cancer Immunotherapy
4820 - Leveraging Stage-Specific Promoters to Enhance Immune Cell Engineering in iPSC-Derived Cells for Cancer Immunotherapy
Pérez Artigas, M. D. M.
405 - The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC
5148 - Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
5148 - Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
Perez Botero, J.
Perez Burbano, G. E.
308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
Perez Ceballos, E.
Perez Ceballos, E.
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
3109 - Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience
3109 - Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience
Pérez de Camino Gaisse, B.
Perez de Oteyza, J.
365 - Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study
Pérez del Río, E.
Perez Encinas, M.
319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
4549 - Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
4549 - Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Perez, F. A.
Pérez, F.
Pérez Galán, P.
Perez Galan, P.
Perez Gonzalez, A.
1838 - Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group
2129 - Donor Chimerism Monitorization for Relapse Prediction in Ex-Vivo CD34-Selected Allogenic Hematopoietic Stem Cell Transplant
3545 - Long-Term Outcomes and Late Complications of Allogeneic Stem Cell Transplant with CD34+ Positive Selection in Adults with Acute Leukaemia and Myelodysplastic Syndrome: A Single-Centre Study
2129 - Donor Chimerism Monitorization for Relapse Prediction in Ex-Vivo CD34-Selected Allogenic Hematopoietic Stem Cell Transplant
3545 - Long-Term Outcomes and Late Complications of Allogeneic Stem Cell Transplant with CD34+ Positive Selection in Adults with Acute Leukaemia and Myelodysplastic Syndrome: A Single-Centre Study
Perez, J. A.
Perez Lafuente, M.
Perez, L.
Perez, L.
1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia
Pérez López, E.
2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
2156 - Sativex Oromucosal Spray in Patients with Chronic Graft Versus Host Disease: Effect on Sclerodermal Features and Refractory Muscle Cramps
3531 - Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)
4884 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth
2156 - Sativex Oromucosal Spray in Patients with Chronic Graft Versus Host Disease: Effect on Sclerodermal Features and Refractory Muscle Cramps
3531 - Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)
4884 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth
Perez Lopez, R.
241 - Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia
1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
4549 - Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms
1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
4549 - Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms
Perez Martinez, A.
112 - “Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
3463 - Alloreactive Vs IL15 Ex Vivo Stimulated Natural Killer Cells As Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Acute Leukemia: A Phase I/II Clinical Trial
3463 - Alloreactive Vs IL15 Ex Vivo Stimulated Natural Killer Cells As Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Acute Leukemia: A Phase I/II Clinical Trial
Perez, M.
Pérez Míguez, C.
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
1938 - Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Multiple Myeloma Diagnosis and Monitoring
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
2708 - Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3593 - Automated Image Analysis Pipeline for Standardized Processing, Segmentation, and Feature Extraction in Diffuse Large B-Cell Lymphoma Histological Slides: Towards Enhanced Prediction of Immunotherapy Response and Risk Stratification
3606 - Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Non-Hodgkin Lymphoma Diagnosis and Screening
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
1938 - Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Multiple Myeloma Diagnosis and Monitoring
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
2708 - Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3593 - Automated Image Analysis Pipeline for Standardized Processing, Segmentation, and Feature Extraction in Diffuse Large B-Cell Lymphoma Histological Slides: Towards Enhanced Prediction of Immunotherapy Response and Risk Stratification
3606 - Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Non-Hodgkin Lymphoma Diagnosis and Screening
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Perez Montes, R.
Perez Perez, A.
Perez Persona, E.
Perez, P.
Pérez, R. F.
Perez Roca, C.
Pérez Ruixo, C.
Pérez Sala, M.
1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
Perez Samano, D. D. J.
Pérez, S.
1715 - Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
Perez Santaolla, E.
Perez Simon, J. A.
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
2874 - A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
2874 - A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Perez-Amill, L.
Perez-Corral, A.
Perez-Cruz, I.
Pérez-Encinas, M.
Perez-Feliz, S.
Pérez-Lamas, L.
Perez-Lugo, L.
Pérez-Martínez, A.
Pérez-Rojas, A. K.
Perez-Salvia, M.
Pérez-Simón, J. A.
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
2096 - Assessing CAR-T Cell Product Quality: The Crucial Role of Metabolic and Persistence Analysis after Antigen Stimulation
2188 - Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
3395 - Role of Antiapoptotic Protein Mcl1 in Graft-Versus-Host Disease
3478 - Innovative Bone Marrow CAR-T Cell Manufacturing for AML: Enhancing Viability and Tumor Migration
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
2096 - Assessing CAR-T Cell Product Quality: The Crucial Role of Metabolic and Persistence Analysis after Antigen Stimulation
2188 - Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
3395 - Role of Antiapoptotic Protein Mcl1 in Graft-Versus-Host Disease
3478 - Innovative Bone Marrow CAR-T Cell Manufacturing for AML: Enhancing Viability and Tumor Migration
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
Perfetto, M.
Pergantou, H.
Peri, V.
Peri, V.
3013 - Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study
3297 - Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial
4390 - Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)
3297 - Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial
4390 - Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)
Peric, Z.
508 - Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT
3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)
3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)
Perica, K.
Pericak-Vance, M. A.
Perico, M. D.
2294 - Multicentric Standardization of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia Using Multiparametric Flow Cytometry – a Brazilian Society of Bone Marrow Transplantation (SBTMO) Project
5181 - Disparities in Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated in Public Versus Private Services in Brazil: Analysis of the Brazilian Acute Myeloid Leukemia Registry
5181 - Disparities in Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated in Public Versus Private Services in Brazil: Analysis of the Brazilian Acute Myeloid Leukemia Registry
Pericole, F. V.
Perini, G. F.
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
1718 - Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)
3018 - Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study
4422.2 - Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma
1718 - Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)
3018 - Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study
4422.2 - Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma
Perini, T.
Perissinotti, A. J.
Perkey, E.
Perkins, A. R.
Perkins, A. C.
483 - Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis
1000 - Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis
1346 - Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments
1000 - Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis
1346 - Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments
Perkins, B.
Perkins, M. C.
3279 - Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy
Perkins, M.
1105 - Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea
2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease
2508 - Parameters Associated with Improved Peripheral Oxygen Extraction in Sickle Cell Patients Treated with Voxelotor
4875 - Erythroid-Specific Chimerism Analysis after Allogeneic-Hematopoietic Stem Cell Transplantation Using a Human Leukocyte Antigen-Identical Sibling Donor in Sickle Cell Disease Patients
2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease
2508 - Parameters Associated with Improved Peripheral Oxygen Extraction in Sickle Cell Patients Treated with Voxelotor
4875 - Erythroid-Specific Chimerism Analysis after Allogeneic-Hematopoietic Stem Cell Transplantation Using a Human Leukocyte Antigen-Identical Sibling Donor in Sickle Cell Disease Patients
Perl, A. E.
211 - Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
2890 - Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)
4278 - Quantum-First: Deep-Dive Analysis of FMS-like Tyrosine Kinase 3–Internal Tandem Duplication (FLT3-ITD) Detection Methods Utilized for Enrollment and Longitudinal MRD Detection in Newly Diagnosed (nd) Patients (pts) with FLT3-ITD–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
4282 - Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction
1504.3 - Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD–Negative Acute Myeloid Leukemia
2907.1 - A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02
221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
2890 - Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)
4278 - Quantum-First: Deep-Dive Analysis of FMS-like Tyrosine Kinase 3–Internal Tandem Duplication (FLT3-ITD) Detection Methods Utilized for Enrollment and Longitudinal MRD Detection in Newly Diagnosed (nd) Patients (pts) with FLT3-ITD–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
4282 - Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction
1504.3 - Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD–Negative Acute Myeloid Leukemia
2907.1 - A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02
Perna, F.
Perna, S. K.
887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
Pernemalm, M.
Perner, F.
Pernod, G.
Perobelli, L.
Perona Blazquez, A.
Perotti, C.
Perpinello, S.
Perpoint, T.
Perram, J.
Perreault, C.
Perrier, A.
Perrin, L.
Perrin, N.
Perrino, M.
Perrot, A.
362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
549 - Risk of Acute Myeloid Leukemia in Adults with Primary Immune Thrombocytopenia Treated with Thrombopoietin Receptor Agonists: A French Nationwide Population-Based Study
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
1025 - Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial
1975 - Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study
1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)
- Transplant in Myeloma: Who, When, and Why?
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
549 - Risk of Acute Myeloid Leukemia in Adults with Primary Immune Thrombocytopenia Treated with Thrombopoietin Receptor Agonists: A French Nationwide Population-Based Study
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
1025 - Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial
1975 - Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study
1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)
- Transplant in Myeloma: Who, When, and Why?
Perrotta, S.
Perruccio, K.
Perry, A. M.
Perry, A.
Perry, B.
Perry, C.
Perry, D.
Perry, J. F.
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy
Perry, J. R.
Perry, J.
Perry, J. M.
Perry, R.
Perry, T.
Persaud, S.
Persaud, S. P.
Persaud, S.
Persaud, Y.
Persigehl, T.
Persinger, J.
Persky, D. O.
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1649 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1649 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study
Persson, B.
Perticari, G.
Pertiñez, L.
Perualila, N.
Perumal Kalaiyarasi, J.
Perusini, M. A.
1506 - Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis
1768 - Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients
3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
3810 - Retrospective Evaluation of BCR::ABL Kinase Domain Mutation Profiles and Treatment Outcomes in Patients with Chronic Myeloid Leukemia to Confirm Clinical Relevance of in Vitro Sensitivity-Based Treatment Switch: Real-World Experience
5193 - What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?
1768 - Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients
3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
3810 - Retrospective Evaluation of BCR::ABL Kinase Domain Mutation Profiles and Treatment Outcomes in Patients with Chronic Myeloid Leukemia to Confirm Clinical Relevance of in Vitro Sensitivity-Based Treatment Switch: Real-World Experience
5193 - What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?
Perutelli, F.
762 - Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation
1854 - Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia
4621 - Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study
1854 - Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia
4621 - Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study
Peruzzo, L.
Pesa, J.
2324 - A Retrospective Database Analysis of Healthcare Resource Utilization in Patients with Warm Autoimmune Hemolytic Anemia in the United States
3705 - Sentiment Analysis Applied to Digital Conversations Among Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Receiving Rituximab and/or Blood Transfusion
3705 - Sentiment Analysis Applied to Digital Conversations Among Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Receiving Rituximab and/or Blood Transfusion
Pesce, F.
Pesce-Noga, R.
1184 - Platelet Transfusion-Sparing Regimens for Severe Thrombocytopenia in Patients Undergoing Autologous Stem Cell Transplantation - a Comparative Retrospective Analysis
1270 - Tolerance of Anemia: Autologous Stem Cell Transplantation Among Bloodless Medicine Patients Can be Safely Conducted at Lower Hemoglobin Thresholds
1270 - Tolerance of Anemia: Autologous Stem Cell Transplantation Among Bloodless Medicine Patients Can be Safely Conducted at Lower Hemoglobin Thresholds
Pescetelli, I.
Pescia, C.
Peseski, A. M.
Peshin, S.
Peshkova, A. D.
Peshwa, M. V.
Pession, A.
Petäjä, J.
Petchler, C.
Petentler, K.
Peterka, B.
Peterkin, K.
Peterlin, P.
58 - Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study
227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
1531 - Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy
1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
2137 - Reconstitution and Licensing of Natural Killer Cells Following T-Cell Replete Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide and Antithymocyte Globulin
2876 - ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction
2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
3506 - Letermovir Provides Protection Against Clinically Significant CMV Infections in CMV-Seronegative Recipients of an Allotransplant from a CMV-Seropositive Donor
4882 - Treosulfan Vs Busulfan As Part of Clofarabine Based Reduced Intensity Conditioning Regimen before Allotransplant for Myeloid Malignancies
227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
1531 - Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy
1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
2137 - Reconstitution and Licensing of Natural Killer Cells Following T-Cell Replete Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide and Antithymocyte Globulin
2876 - ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction
2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
3506 - Letermovir Provides Protection Against Clinically Significant CMV Infections in CMV-Seronegative Recipients of an Allotransplant from a CMV-Seropositive Donor
4882 - Treosulfan Vs Busulfan As Part of Clofarabine Based Reduced Intensity Conditioning Regimen before Allotransplant for Myeloid Malignancies
Peters, C.
3540 - Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party
3563 - Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial
4864 - Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study
3563 - Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial
4864 - Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study
Peters, D. T.
62 - Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML
324 - Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium
1481 - Azacitidine and Venetoclax with or without Donor Lymphocyte Infusion in Relapsed AML Post Allo-HSCT: A Single-Institution Retrospective Study
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
324 - Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium
1481 - Azacitidine and Venetoclax with or without Donor Lymphocyte Infusion in Relapsed AML Post Allo-HSCT: A Single-Institution Retrospective Study
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
Peters, F. S.
Peters, M.
Peters, M.
129 - Postpartum Hemorrhage in Hemophilia a and B Carriers after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2595 - Postpartum Hemorrhage in Women with Von Willebrand Disease after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2601 - The Influence of Postpartum Hemorrhage on Patient Reported Outcomes Among Women with Von Willebrand Disease: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2595 - Postpartum Hemorrhage in Women with Von Willebrand Disease after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2601 - The Influence of Postpartum Hemorrhage on Patient Reported Outcomes Among Women with Von Willebrand Disease: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
Peters, R. T.
2198 - In Vivo Hematopoietic Stem Cell Engineering Restores the Function of NADPH Enzyme Complex in X-Linked Chronic Granulomatous Disease Model Mice
4770 - Single Dose of Tgroβ (EN-145)/Plerixafor Safely and Effectively Mobilizes Primitive HSCs in Mouse Models for In Vivo Gene Therapy of Sickle Cell Disease
4770 - Single Dose of Tgroβ (EN-145)/Plerixafor Safely and Effectively Mobilizes Primitive HSCs in Mouse Models for In Vivo Gene Therapy of Sickle Cell Disease
Peters, S.
Petersdorf, E. W.
Petersen, J.
1087 - Risk of Fractures in Individuals with Hemochromatosis HFE C282Y Homozygosity and in Individuals with Low or High Levels of Plasma Iron, Transferrin Saturation, or Ferritin: A Prospective Study of 142,146 General Population Individuals
3334 - Absolute Risk of Multiple Myeloma Is Quite Modest in Individuals with Incidentally Discovered Vertebral Fractures: A Prospective Cohort Study of 9,065 CT-Scanned Danish General Population Individuals with Independent Validation in a UK General Population Cohort
3831 - Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II – Results from the 8-Week Dose-Escalation Period
3334 - Absolute Risk of Multiple Myeloma Is Quite Modest in Individuals with Incidentally Discovered Vertebral Fractures: A Prospective Cohort Study of 9,065 CT-Scanned Danish General Population Individuals with Independent Validation in a UK General Population Cohort
3831 - Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II – Results from the 8-Week Dose-Escalation Period
Petersen, M.
Petersen, S. L.
112 - “Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
965 - Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
965 - Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
Petersheim, D.
Petersohn, S.
Peterson, A.
Peterson, C.
Peterson, C.
Peterson, K. R.
Peterson, N. A.
Petit, A.
310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes
968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
Petrakis, G.
Petranovic, D.
Petrassi, H. M.
Petrelli, F.
Petrera, A.
Petri, M.
Petrichenko, A.
Petrilli, D.
Petrillo, S.
Petrone, G.
Petrosyants, A.
Petrovski, S.
Petrucci, M. T.
674 - Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study
Petrusca, D. N.
Petruski-Ivleva, N.
Petruzziello, F.
Petterson, T.
1097 - Donor Trait Status Determines Haematological Outcomes Post-Haemopoietic Stem Cell Transplantation in Transfusion Dependent Thalassaemia Independent of HLA Matching and Chimerism Status
3518 - Abatacept Abrogates the Risk of Acute GvHD in Both Matched and Mismatched Transplantation for Haemoglobinopathies and Bone Marrow Failure
3518 - Abatacept Abrogates the Risk of Acute GvHD in Both Matched and Mismatched Transplantation for Haemoglobinopathies and Bone Marrow Failure
Pettersson, E.
Pettijohn, E. M.
Pettit, A.
Pettit, A.
Pettit, K.
Pettit, K. M.
481 - A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia
1787 - Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors
2800 - Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis
4559 - Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
1787 - Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors
2800 - Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis
4559 - Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
Pettitt, A.
Petzold, T.
Pevnev, G.
Pezzin, L. E.
Pfaff, K.
Pfannenstiell, K.
2122 - Sociodemographic and Patient-Related Determinants of Outcomes after Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3503 - Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
3524 - Sociodemographic and Patient-Related Determinants of Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3503 - Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
3524 - Sociodemographic and Patient-Related Determinants of Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
Pfeffer, D.
Pfeffer, L. K.
Pfeiffer, A.
Pfeiffer, S.
Pfeiffer, T.
375 - Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity
2088.1 - NK Cell Immunotherapy to Reduce Relapse after Haploidentical Transplant for High-Risk Pediatric and Young Adult AML
2088.1 - NK Cell Immunotherapy to Reduce Relapse after Haploidentical Transplant for High-Risk Pediatric and Young Adult AML
Pfirrmann, M.
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
1774 - The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients
1774 - The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients
Pfister, S.
Pfister, V.
2348 - Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL
4413 - Importance of Access Inequality and Biological Prognostic Factors in Mantle Cell Lymphoma Outcomes in Brazil: A Real-World Evidence Study from a Third World Country
5181 - Disparities in Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated in Public Versus Private Services in Brazil: Analysis of the Brazilian Acute Myeloid Leukemia Registry
4413 - Importance of Access Inequality and Biological Prognostic Factors in Mantle Cell Lymphoma Outcomes in Brazil: A Real-World Evidence Study from a Third World Country
5181 - Disparities in Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated in Public Versus Private Services in Brazil: Analysis of the Brazilian Acute Myeloid Leukemia Registry
Pfitzer, J. C.
Pfrepper, C.
Phadnis, D.
Pham Hung D'Alexandry D'Orengiani, A. L.
290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease
3890 - Protection Against Coronary Atherosclerosis in High Cardiovascular Risk Sickle Cell Disease Patients: A Beneficial Role of Intravascular Hemolysis?
3891 - Unique Nature of Sickle Cell Diastolic Cardiomyopathy: A Tailored Echocardiographic Definition to Refine Prognostic Stratification in Young Adults
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease
3890 - Protection Against Coronary Atherosclerosis in High Cardiovascular Risk Sickle Cell Disease Patients: A Beneficial Role of Intravascular Hemolysis?
3891 - Unique Nature of Sickle Cell Diastolic Cardiomyopathy: A Tailored Echocardiographic Definition to Refine Prognostic Stratification in Young Adults
Pham, J.
1363 - Defining the Roles of Base Deaminase and Splicing Deregulation in Pediatric B-Cell Acute Lymphoblastic Leukemia Stem Cell Persistence
1385 - Identifying the Impact of ADAR1 Inhibition on LSC Niche Remodeling in 3D Nanobioreactors
4068 - A 3D Niche Nanobioreactor Supports Long-Term Tracking of Hematopoietic Stem and Progenitor Cell Cycle Kinetics, Self-Renewal and Cell Fate Determination
1385 - Identifying the Impact of ADAR1 Inhibition on LSC Niche Remodeling in 3D Nanobioreactors
4068 - A 3D Niche Nanobioreactor Supports Long-Term Tracking of Hematopoietic Stem and Progenitor Cell Cycle Kinetics, Self-Renewal and Cell Fate Determination
Pham, L. D.
Pham, L. L.
Pham, T. T. D.
Phang, B. H.
Phang, T.
Phang, T.
Phelan, J. D.
229 - Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes
451 - Genetic Subclones Reveal Phenotypic Heterogeneity in Diffuse Large B-Cell Lymphoma
750 - Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
984 - Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
1724 - A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS
451 - Genetic Subclones Reveal Phenotypic Heterogeneity in Diffuse Large B-Cell Lymphoma
750 - Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
984 - Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
1724 - A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS
Phelps, M. A.
Phelps-Bergeron, Z.
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
Philbrook, B.
Philbrook, S.
Philip, B.
Philip, K.
Philip, L.
Philip, R.
Philipovskiy, A.
3215 - Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
4757.2 - Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA)
4757.2 - Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA)
Philipp, U.
Philippar, U.
212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
949 - CRISPR/Cas9 Library Screens Identified Atp2a2 As an In Vivo Specific Tumor Suppressor in Myeloid Neoplasms
1408 - JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models
2054 - Discovery of JNJ-89853413, a First-in-Class CD33xVδ2 T-Cell Engager for the Treatment of Acute Myeloid Leukemia
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
949 - CRISPR/Cas9 Library Screens Identified Atp2a2 As an In Vivo Specific Tumor Suppressor in Myeloid Neoplasms
1408 - JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models
2054 - Discovery of JNJ-89853413, a First-in-Class CD33xVδ2 T-Cell Engager for the Treatment of Acute Myeloid Leukemia
Philippe, A.
Philips, B. J.
178 - A Phase 1b/2 Study of the Efficacy and Safety of Combination Hydroxyurea and Dose-Escalated Erythropoietin for Treatment of Anemia in Sickle Cell Disease (ACHiEvE-SCD)
294 - Higher Hemoglobin Level Correlates with Increased Tissue Oxygenation in a Comprehensive Profile of Hemorheology in Sickle Cell Disease
1111 - Daprodustat Induces Fetal Hemoglobin and Erythropoietic Drive in an in Vitro and In Vivo Model of Sickle Cell Disease
3861 - Inhibition of Purine Nucleoside Phosphorylase Is a Promising Anti-Sickling Approach for Sickle Cell Disease
294 - Higher Hemoglobin Level Correlates with Increased Tissue Oxygenation in a Comprehensive Profile of Hemorheology in Sickle Cell Disease
1111 - Daprodustat Induces Fetal Hemoglobin and Erythropoietic Drive in an in Vitro and In Vivo Model of Sickle Cell Disease
3861 - Inhibition of Purine Nucleoside Phosphorylase Is a Promising Anti-Sickling Approach for Sickle Cell Disease
Philipsen, S.
Phillip, R.
Phillips, A. A.
Phillips, C. L.
71 - Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)
2412 - Impact of Extramedullary Disease on the Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Acute Myeloid Leukemia - a CIBMTR Analysis
2817 - Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study
2846 - GWAS Identifies Pharmacogenetic Markers Associated with Premedication-Related Pegaspargase Hypersensitivity and Toxicities in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma
2412 - Impact of Extramedullary Disease on the Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Acute Myeloid Leukemia - a CIBMTR Analysis
2817 - Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study
2846 - GWAS Identifies Pharmacogenetic Markers Associated with Premedication-Related Pegaspargase Hypersensitivity and Toxicities in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma
Phillips, D. C.
Phillips, D. M.
Phillips, E.
Phillips, E. H.
4744 - Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial
1674.1 - Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
1674.1 - Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
Phillips, L.
Phillips, N. S.
Phillips, N.
Phillips, S.
Phillips, T. J.
1631 - Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study
1633 - Acalabrutinib, Umbralisib and Ublituximab Regimen (AU2) Demonstrates High Response Rate and Undetectable Molecular Minimal Residual Disease (MRD) in Patients (pts) with De Novo Mantle Cell Lymphoma (MCL)
1703 - Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study
2278 - Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible
2349 - Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3115 - Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
3732 - Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)
4477 - Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
4491 - Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy
5097 - Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1633 - Acalabrutinib, Umbralisib and Ublituximab Regimen (AU2) Demonstrates High Response Rate and Undetectable Molecular Minimal Residual Disease (MRD) in Patients (pts) with De Novo Mantle Cell Lymphoma (MCL)
1703 - Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study
2278 - Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible
2349 - Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3115 - Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
3732 - Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)
4477 - Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
4491 - Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy
5097 - Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phojanakong, P.
723 - CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition
1038 - HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies
2036 - Structure Guided Design of CCL27 CAR T-Cells Against CCR10 for Multiple Myeloma
4646 - CD48: Friend or Foe in NK-Cell Immunosurveillance of Multiple Myeloma?
1038 - HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies
2036 - Structure Guided Design of CCL27 CAR T-Cells Against CCR10 for Multiple Myeloma
4646 - CD48: Friend or Foe in NK-Cell Immunosurveillance of Multiple Myeloma?
Phua, C. W.
Phull, P.
1946 - Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)
2408 - Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis
3316 - Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
2408 - Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis
3316 - Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
Phuong, P. H.
Pi, Y.
Pianese, J.
Pianko, M.
496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
3264 - Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
3379 - Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy – First Report from the Maestro Trial
4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
3264 - Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
3379 - Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy – First Report from the Maestro Trial
4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Piao, M.
Piasevoli, K.
Piatek, C.
2324 - A Retrospective Database Analysis of Healthcare Resource Utilization in Patients with Warm Autoimmune Hemolytic Anemia in the United States
2692 - Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial
3705 - Sentiment Analysis Applied to Digital Conversations Among Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Receiving Rituximab and/or Blood Transfusion
2692 - Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial
3705 - Sentiment Analysis Applied to Digital Conversations Among Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Receiving Rituximab and/or Blood Transfusion
Piault, R.
Piazza, F.
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
3013 - Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)
3013 - Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)
Piazza, G.
Piazza, G.
Piazza, R.
Piboonvaranggoon, J.
Pica, G. M.
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
846 - Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
1518 - Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group
4479 - Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa
846 - Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
1518 - Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group
4479 - Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa
Picardi, A.
1809 - A Study on the Effect of Luspatercept on Regulatory T Cells and Myeloid Derived Suppressor Cells in Low Risk Myelodysplastic Syndrome with Ring Sideroblasts
2095 - Gelofusine As Alternative to Dextran40 for Washing Cryopreserved Hematopoietic Stem Cell Products Prior to Infusion: Validation and Application to Clinical Practice
2126 - Evidence-Based Choice of Conditioning Regimen for Hematopoietic Stem Cell Transplantation (HSCT) in Acute Leukemia: The Italian Cellular Therapy and Stem Cell Transplant Group (GITMO) Guidelines
2095 - Gelofusine As Alternative to Dextran40 for Washing Cryopreserved Hematopoietic Stem Cell Products Prior to Infusion: Validation and Application to Clinical Practice
2126 - Evidence-Based Choice of Conditioning Regimen for Hematopoietic Stem Cell Transplantation (HSCT) in Acute Leukemia: The Italian Cellular Therapy and Stem Cell Transplant Group (GITMO) Guidelines
Picarsic, J.
Piccinelli, S.
Piccini, M.
Piccini, M.
Piccone, C. M.
Pichardo Rodriguez, R. M. D. J.
Pichardo-Almarza, C.
Pichler, A.
Pichler, P.
1967 - Real World Efficacies of First Line Treatments in Non-Transplant-Eligible Newly Diagnosed (ND-NTE) Multiple Myeloma (MM) Patients: A Challenge to Maia ? an Analysis from the Austrian Myeloma Registry (AMR)
2413 - Therapy Management and Outcomes in Newly Diagnosed Unfit AML Patients Receiving Venetoclax + HMA – Insights from a Prospective Real-World Study in Switzerland and Austria
3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group
2413 - Therapy Management and Outcomes in Newly Diagnosed Unfit AML Patients Receiving Venetoclax + HMA – Insights from a Prospective Real-World Study in Switzerland and Austria
3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group
Picinich, A.
Piciocchi, A.
1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
Piciocchi, A.
65 - Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients
274 - Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia
407 - Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
992 - Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network
1872 - Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi
2427 - Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2893 - Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
274 - Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia
407 - Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
992 - Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network
1872 - Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi
2427 - Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2893 - Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
Pick, M.
Pickard, L.
Picken, M. M.
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
Pickering, S.
Pickersgill, F.
Pickett, D.
Pickford, R.
Picone, C.
Pidala, J. A.
695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia
4902 - Cytokines associated with organ manifestations in chronic graft-versus-host disease
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia
4902 - Cytokines associated with organ manifestations in chronic graft-versus-host disease
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
Piehler, J.
Piekarska, A.
1313 - Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab
4915 - Gynecological Graft-Versus-Host Disease Mimics Cervical Intraepithelial Neoplasia in Pap Smear– Single Center Prospective Study
4915 - Gynecological Graft-Versus-Host Disease Mimics Cervical Intraepithelial Neoplasia in Pap Smear– Single Center Prospective Study
Piekarz, R.
Piel, J.
Piemontese, S.
693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
3457 - SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post HLA Mismatched Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Reset-02 First-in-Human Phase I/II
3570 - Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT
4944 - Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
3457 - SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post HLA Mismatched Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Reset-02 First-in-Human Phase I/II
3570 - Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT
4944 - Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Piepenbroek, B.
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
Pieragostini, A.
Pierce, D. W.
957 - BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin’s Lymphoma
1395 - Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)
3104 - Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome
4142 - BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53
1395 - Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)
3104 - Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome
4142 - BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53
Pierce, G.
Pierce, J.
Pierce, K.
Pierce, S.
735 - Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
1511 - Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up
1572 - Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy
1800 - Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations
1842 - Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes
2438 - Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds
2903 - Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4251 - Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
1511 - Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up
1572 - Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy
1800 - Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations
1842 - Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes
2438 - Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds
2903 - Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4251 - Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
Pierceall, W. E.
Pierciey, Jr., F. J.
Pierdomenico, E.
Pierik, F. R.
Pierini, A.
147 - Treg Selection from G-CSF Stimulated Donors Improves Outcomes of Immune-Suppression Free HLA-Haploidentical Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy
269 - Safety of 20Gy Total Marrow Irradiation Based Conditioning Regimen for Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
- Novel Conditioning and Prophylaxis Regimens for Relapse Prevention
269 - Safety of 20Gy Total Marrow Irradiation Based Conditioning Regimen for Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
- Novel Conditioning and Prophylaxis Regimens for Relapse Prevention
Pierola, A. A.
212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
879 - Unveiling ZMAT2 and SMARCD3 As Therapeutic Targets to Mitigate Aberrant Hematopoiesis in MDS
2708 - Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes
2874 - A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma
2883.1 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln‑049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
879 - Unveiling ZMAT2 and SMARCD3 As Therapeutic Targets to Mitigate Aberrant Hematopoiesis in MDS
2708 - Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes
2874 - A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma
2883.1 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln‑049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease
Pierre, A. E.
Pierre-Victor, D.
Pierri, F.
Pierri, S.
Pierson, A.
Pierson, S. K.
Pieters, T.
Pietka, G.
Pietrantuono, G.
1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
Pietras, E. M.
877 - Luspatercept Promotes Heme Biosynthesis and Erythroblast Island Formation in a Novel Low-Risk MDS Mouse Model
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
2671 - Title: In Vivo Clonal Tracing of Hematopoietic Stem and Progenitor Cells Reveals Increased Clonal Heterogeneity during Aging, Alongside Critical Changes in Selection Patterns
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
2671 - Title: In Vivo Clonal Tracing of Hematopoietic Stem and Progenitor Cells Reveals Increased Clonal Heterogeneity during Aging, Alongside Critical Changes in Selection Patterns
Pietrasanta, D.
Pietrini, I.
Pietrobono, S.
Pietrofeso, A.
Pietsch, E. C.
Pievani, A.
Piffaretti, D.
73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
1578 - Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
1578 - Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
Pigazzi, M.
Pigneux, A.
58 - Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study
212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network
227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study
2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4275 - Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network
227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study
2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4275 - Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
Pijning, A. E.
Pika, T.
1999 - A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma
2378 - Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets – Analysis of the Czech Myeloma Group
5156 - Teclistamab in Relapsed and Refractory Multiple Myeloma Patients – Czech Multi-Center Real World Evidence Analysis
2378 - Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets – Analysis of the Czech Myeloma Group
5156 - Teclistamab in Relapsed and Refractory Multiple Myeloma Patients – Czech Multi-Center Real World Evidence Analysis
Pike, A.
Pike, M.
Pikman, Y.
Pilathodan, H.
Pilcher, W.
Pileri, S.
Pilheden, M.
Pilla, A.
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
4556 - Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
4556 - Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
Pillai, M.
1075 - Cytoplasmic Intron Retention As a Regulatory Mechanism of Mitochondrial Homeostasis in Erythroid Cells
1812 - Tet2 Loss in Hematopoietic Stem Cells Triggers Chromatin Reorganization through DNA Methylation Shifts
1813 - SF3B1 Mutations Lead to Changes in Fine-Scale Chromatin Organization through Impaired Transcription
2732 - A Unified Post-Transcriptional Mechanism Regulates Intron Retention in Splicing Factor-Mutant MDS
1812 - Tet2 Loss in Hematopoietic Stem Cells Triggers Chromatin Reorganization through DNA Methylation Shifts
1813 - SF3B1 Mutations Lead to Changes in Fine-Scale Chromatin Organization through Impaired Transcription
2732 - A Unified Post-Transcriptional Mechanism Regulates Intron Retention in Splicing Factor-Mutant MDS
Pillai, P.
462 - Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
3055 - Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
5207 - Analysis of the Hematology Health Equity Literature: Trends By Topic and Disparity, across Journals, and over Time
3055 - Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
5207 - Analysis of the Hematology Health Equity Literature: Trends By Topic and Disparity, across Journals, and over Time
Pillai, R.
775 - Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients
947 - Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation
4776 - Donor T-Derived Memory Progenitors Differentiated into CD103+/- CXCR6+CD4+ Tissue-Resident T Cell Subsets Driven Cutaneous Chronic Graft-Versus-Host Disease
947 - Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation
4776 - Donor T-Derived Memory Progenitors Differentiated into CD103+/- CXCR6+CD4+ Tissue-Resident T Cell Subsets Driven Cutaneous Chronic Graft-Versus-Host Disease
Pillai, S. C.
1896 - Proteasome Shuttle Factor and DNA Repair Protein Rad23A Is a Potential Therapeutic Target in Multiple Myeloma
1905 - 26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma
1947 - Full Spectrum Multi-Parameter Single-Tube Flow Cytometry Analysis for Cross-Sectional Immune-Profiling of Natural Killer Cells in Multiple Myeloma Clinical Samples
1905 - 26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma
1947 - Full Spectrum Multi-Parameter Single-Tube Flow Cytometry Analysis for Cross-Sectional Immune-Profiling of Natural Killer Cells in Multiple Myeloma Clinical Samples
Pillai, V.
Pillon, M.
Pilo, F.
Pilo, F.
Pimanda, J. E.
Pimentel, A.
Pimienta, S.
Pimkova, K.
Pina-Oviedo, S.
Pinachyan, K.
Piñana, J. L.
2105 - Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)
4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)
Pinaud, E.
Pinchinat, A.
Pineault, N.
Pineda-Roman, M.
3769 - Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center
4751 - Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy
4751 - Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy
Piñeiro Fiel, M.
1938 - Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Multiple Myeloma Diagnosis and Monitoring
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
3593 - Automated Image Analysis Pipeline for Standardized Processing, Segmentation, and Feature Extraction in Diffuse Large B-Cell Lymphoma Histological Slides: Towards Enhanced Prediction of Immunotherapy Response and Risk Stratification
3606 - Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Non-Hodgkin Lymphoma Diagnosis and Screening
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
3593 - Automated Image Analysis Pipeline for Standardized Processing, Segmentation, and Feature Extraction in Diffuse Large B-Cell Lymphoma Histological Slides: Towards Enhanced Prediction of Immunotherapy Response and Risk Stratification
3606 - Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Non-Hodgkin Lymphoma Diagnosis and Screening
Piñero, M.
Pingali, S. R.
Pingali, S. R. K.
Pinheiro, A. S.
Pinheiro, A. A. S.
Pinheiro, L. H.
Pinheiro, L. H.
Pinho, S.
2 - Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging
3589 - PIM447, a Pan-PIM Kinase Inhibitor, in Combination with Venetoclax Exerts a Potent Anti-Tumor Activity in the Bone Marrow Niche
4968 - Novel MET Inhibitors Provide a Therapeutic Opportunity for AML By Overcoming the Protective Action of the Bone Marrow Niche
3589 - PIM447, a Pan-PIM Kinase Inhibitor, in Combination with Venetoclax Exerts a Potent Anti-Tumor Activity in the Bone Marrow Niche
4968 - Novel MET Inhibitors Provide a Therapeutic Opportunity for AML By Overcoming the Protective Action of the Bone Marrow Niche
Pinho Vaz, C.
Pini, K.
73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
Pinilla-Ibarz, J.
Pinilla-Ibarz, J.
993 - Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia
1744 - Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
1848 - Identifying the Role of Endoplasmic Reticulum Stress in CLL T-Cell Dysfunction
1866 - Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies
2426 - Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium
2820 - Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
3021 - Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis
3065 - A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma
3742 - Association Between Dose Reduction and Duration of Therapy in Patients Receiving Ibrutinib or Acalabrutinib for Chronic Lymphocytic Leukemia: A Medical Chart Review Study
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4803 - Reprogramming CLL T-Cell Mitochondrial Fitness Using PI3K Inhibition for Enhancing CAR T-Cell Therapy
5052 - U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)
1744 - Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
1848 - Identifying the Role of Endoplasmic Reticulum Stress in CLL T-Cell Dysfunction
1866 - Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies
2426 - Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium
2820 - Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
3021 - Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis
3065 - A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma
3742 - Association Between Dose Reduction and Duration of Therapy in Patients Receiving Ibrutinib or Acalabrutinib for Chronic Lymphocytic Leukemia: A Medical Chart Review Study
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4803 - Reprogramming CLL T-Cell Mitochondrial Fitness Using PI3K Inhibition for Enhancing CAR T-Cell Therapy
5052 - U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)
Pinkle, D.
Pinkston, P.
Pinkus, G.
Pinnix, C. C.
1679 - Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases
4182 - CNS Involvement in Adult Patients with B-Cell Acute Lymphoblastic Leukemia
4377 - Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy
4434.2 - CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab
4182 - CNS Involvement in Adult Patients with B-Cell Acute Lymphoblastic Leukemia
4377 - Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy
4434.2 - CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab
Pinocchio, N.
104 - Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3137 - Unveiling MED12L: A Potential Novel Orchestrator of Platelet Dysfunction in Myeloproliferative Myeloid Neoplasms
3194 - Single-Cell Multi-Omics Reveals Anticipated Erythroid Differentiation and Transcriptional Regulation in Differentiation Trajectories of SF3B1 - JAK2/MPL Mutated Cells in MDS/MPN-RS-T
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3137 - Unveiling MED12L: A Potential Novel Orchestrator of Platelet Dysfunction in Myeloproliferative Myeloid Neoplasms
3194 - Single-Cell Multi-Omics Reveals Anticipated Erythroid Differentiation and Transcriptional Regulation in Differentiation Trajectories of SF3B1 - JAK2/MPL Mutated Cells in MDS/MPN-RS-T
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
Pinos Cabezas, I.
Pintar, S. M.
Pinter-Brown, L. C.
3056 - Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule
3061 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
4433 - Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors
3061 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
4433 - Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors
Pinto, A.
Pinto, A.
469 - Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
988 - Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study
1580 - Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients
1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
1634 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study
3046 - Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
4449 - A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma
988 - Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study
1580 - Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients
1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
1634 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study
3046 - Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
4449 - A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma
Pinto, D. M.
Pinto, F.
Pinto, N. R.
Pinto Pereira, M.
Pinto, V. M.
Pinz, K. G.
Pinzón-Ramírez, Y. V.
Pioltelli, M. L.
Piorczynski, T. B.
336 - Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas
973 - Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma
3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
973 - Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma
3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
Pipe, S. W.
128 - Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE
1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
1214 - Bleed Patterns in Infants, from Birth to 12 Months of Age, with Hemophilia A Treated with Emicizumab: Exploratory Analysis of the HAVEN 7 Study
3972 - Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors
2593.1 - Become–9: A Phase 1/2 Dose Escalation and Expansion Study of be-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B
1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
1214 - Bleed Patterns in Infants, from Birth to 12 Months of Age, with Hemophilia A Treated with Emicizumab: Exploratory Analysis of the HAVEN 7 Study
3972 - Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors
2593.1 - Become–9: A Phase 1/2 Dose Escalation and Expansion Study of be-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B
Piquer Monsonis, L.
Piqueras, M. D. C.
Pirenne, F.
1105 - Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea
2608 - Red Blood Cell-Derived Particles Induce Endothelial Damage Via the Alternative Complement Pathway
4875 - Erythroid-Specific Chimerism Analysis after Allogeneic-Hematopoietic Stem Cell Transplantation Using a Human Leukocyte Antigen-Identical Sibling Donor in Sickle Cell Disease Patients
2608 - Red Blood Cell-Derived Particles Induce Endothelial Damage Via the Alternative Complement Pathway
4875 - Erythroid-Specific Chimerism Analysis after Allogeneic-Hematopoietic Stem Cell Transplantation Using a Human Leukocyte Antigen-Identical Sibling Donor in Sickle Cell Disease Patients
Pires Marafon, J.
Pires, T.
Piris Villaespesa, M.
Piris-Villaespesa, M.
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
Piriyakhuntorn, P.
Pirosa, M. C.
Pirosa, M. C.
73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
1578 - Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
4356 - Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
1578 - Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
4356 - Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy
Pirrone, R.
Pirrotte, P.
Piryani, S. O.
Pisani, I.
Pisano, V.
Piseddu, I.
Pishko, A. M.
Pishyar, S.
Pita-Juarez, Y.
3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
Pitangueira, H.
Pitkänen, E.
Pitman, J.
Pitone, M. L.
605 - Empowering Adolescents and Young Adults with Sickle Cell Disease: Development of a Shared Decision-Making Toolkit for Disease-Modifying Therapies
3627 - Development of an Age-Appropriate, Multi-Media Educational Digital Hub for Adolescents with Sickle Cell Trait
5008 - Sctalk: A Pilot Trial Using Implementation Science to Improve Documentation and Disclosure of Sickle Cell Trait during Infancy
3627 - Development of an Age-Appropriate, Multi-Media Educational Digital Hub for Adolescents with Sickle Cell Trait
5008 - Sctalk: A Pilot Trial Using Implementation Science to Improve Documentation and Disclosure of Sickle Cell Trait during Infancy
Pittaluga, S.
231 - Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement– an L.L.M.P.P. Study
750 - Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
984 - Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
1724 - A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS
750 - Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
984 - Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
1724 - A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS
Pittari, G.
Pittman, K.
Pittman, T.
Pitton, C. N.
Piussi, R.
Pivneva, I.
Piwnica-Worms, D.
Piyanzin, S.
Pizzarella, D.
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
Pizzi, M.
Pizzo, A.
Pizzo, L.
Pizzolo, G.
Pizzuti, M.
1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
Pizzuti, V. J.
Place, A. E.
307 - Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study
Place, R. F.
Plank, T.
Planoutene, M.
Plantamura, E.
Plante, T. B.
Plantevin-Krenitsky, V.
Plantier, I.
1434 - Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
Plas, W.
Plasencia, A.
Plastaras, J. P.
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
5123 - Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2nd Line CAR T Therapy
5123 - Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2nd Line CAR T Therapy
Plastira, C.
Platt, E.
Plattel, W.
2984 - Unveiling Transformation Mechanisms of Nodal Marginal Zone Lymphoma Using a Multi-Omics Approach
3044 - Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial
3371 - Long-Term Follow-up from the Phase 2 ICON Study of Iberdomide Combined with Low-Dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd)
4428 - Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial
3044 - Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial
3371 - Long-Term Follow-up from the Phase 2 ICON Study of Iberdomide Combined with Low-Dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd)
4428 - Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial
Platten, M.
Platzbecker, U.
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
350 - Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent–Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial
352 - Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
353 - Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
404 - The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
708 - Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1341 - Mutant Idh1 Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs
1818 - Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial
1832 - Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial
1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
1845 - Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1del5q): Outcomes and Response to Treatment
1877 - The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution
2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
2094 - Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma
2158 - CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
2875 - Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
2948 - HLA‑DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
3210 - Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
3216 - Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study
3221 - Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS
3222 - A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study
3225 - Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4046 - Luspatercept Reduces Clonal Hematopoiesis-Associated Cardiac Stress Via Modulation of mTORC1 and Inflammatory Signaling Pathways
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4334 - Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia
4337 - Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission
4590 - Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial
1845.1 - Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)
3228.1 - Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
350 - Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent–Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial
352 - Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
353 - Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
404 - The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
708 - Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1341 - Mutant Idh1 Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs
1818 - Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial
1832 - Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial
1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
1845 - Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1del5q): Outcomes and Response to Treatment
1877 - The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution
2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
2094 - Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma
2158 - CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
2875 - Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
2948 - HLA‑DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
3210 - Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
3216 - Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study
3221 - Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS
3222 - A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study
3225 - Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4046 - Luspatercept Reduces Clonal Hematopoiesis-Associated Cardiac Stress Via Modulation of mTORC1 and Inflammatory Signaling Pathways
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4334 - Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia
4337 - Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission
4590 - Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial
1845.1 - Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)
3228.1 - Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
Playà-Albinyana, H.
1371 - The SOX11 Interactome Reveals the SOX11:SMARCA4 Complex As a Driver of Oncogenic Transcriptional Programs in Mantle Cell Lymphoma
3231 - T Cells from CLL Patients on Venetoclax Mount Potent Cytotoxic Responses in Combination with Epcoritamab, a CD20/CD3 Bispecific Antibody
3234 - A Novel 3D Hydrogel Culture System Mimics the Lymph Node and Induces CLL Survival and Proliferation
3231 - T Cells from CLL Patients on Venetoclax Mount Potent Cytotoxic Responses in Combination with Epcoritamab, a CD20/CD3 Bispecific Antibody
3234 - A Novel 3D Hydrogel Culture System Mimics the Lymph Node and Induces CLL Survival and Proliferation
Plebani, S.
Plenteda, C.
Plesner, T.
Plesner, T.
Plessmann, U.
Plevniak, K.
Plevritis, S.
Pleyer, C.
Pleyer, C.
Pleyer, L.
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group
Plo, I.
752 - Amplification of Von Willebrand Factor-Positive CALRmut Disease-Initiating Hematopoietic Stem Cells Is Associated to the Activation of the PERK/EiF2a Branch of Unfolded Protein Response
LBA-2 - Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis
LBA-2 - Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis
Ploeg, van der, L.
Ploeger, H.
Ploense, K.
Plonkova, H.
1887 - Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment
1962 - Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients
1999 - A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma
3270 - Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma
1962 - Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients
1999 - A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma
3270 - Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma
Plonski, F.
1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
3577 - Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
3577 - Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety
Plotkin, E.
Ploumakis, A.
Pluchart, C.
1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
LBA-5 - Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
LBA-5 - Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities
Pluta, A.
970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)
Pobischan, A.
Pochintesta, L.
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
Pochon, C.
596 - Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
4075 - Upfront HSCT with an Alemtuzumab Based Conditioning Regimen in Children with Acquired Aplastic Anemia: A Retrospective Study from the SFGM-TC
4864 - Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
4075 - Upfront HSCT with an Alemtuzumab Based Conditioning Regimen in Children with Acquired Aplastic Anemia: A Retrospective Study from the SFGM-TC
4864 - Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study
Podar, K.
1967 - Real World Efficacies of First Line Treatments in Non-Transplant-Eligible Newly Diagnosed (ND-NTE) Multiple Myeloma (MM) Patients: A Challenge to Maia ? an Analysis from the Austrian Myeloma Registry (AMR)
4662 - DDX3X Promotes Multiple Myeloma Cell Survival and Proteasome Inhibitor Resistance through Modulation of Stress Granule Assembly and MAPKAPK2 Translation
4662 - DDX3X Promotes Multiple Myeloma Cell Survival and Proteasome Inhibitor Resistance through Modulation of Stress Granule Assembly and MAPKAPK2 Translation
Podda, G. M.
Poddar, N.
Poddar, S.
864 - 5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
4368 - Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel
4368 - Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel
Podlucky, J.
Podolnikova, N. P.
Podolsky, S.
Podoltsev, N. A.
736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
788 - Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia
1480 - Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia
2319 - Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database
2445 - Educational Impact of Live and Online Enduring CME Activities Presented at the 65th ASH Annual Meeting on Hematology/Oncology Specialists Evaluated Using Pre-/Post-Education Assessments
3644 - Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4253 - Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4585 - Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
788 - Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia
1480 - Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia
2319 - Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database
2445 - Educational Impact of Live and Online Enduring CME Activities Presented at the 65th ASH Annual Meeting on Hematology/Oncology Specialists Evaluated Using Pre-/Post-Education Assessments
3644 - Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4253 - Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4585 - Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
Poeck, H.
264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
840 - Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
840 - Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Poeck, H.
Poelsler, G.
Poeschel, S.
Pogosova-Agadjanyan, E. L.
Poh, C.
783 - Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
1666 - Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
1684 - Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
3069 - Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
5116 - Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma
1661.2 - A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress
1674.1 - Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)
4634.2 - Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial
LBA-1 - Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
1666 - Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
1684 - Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
3069 - Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
5116 - Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma
1661.2 - A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress
1674.1 - Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)
4634.2 - Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial
LBA-1 - Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
Pohl, C.
Pohl, M. A.
Poiani, M.
Poigaialwar, G.
Poigailwar, G.
Poiré, X.
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
2188 - Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
4946 - Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK–Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)
2188 - Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
4946 - Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK–Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)
Poirier, N.
Poisa-Beiro, L.
Pokharel, S.
Pokhrel, A.
Pokhrel, B.
Pokhriyal, S. C.
Pokima, N.
Pokorna, E.
Polansky-Biskup, J.
Polar, M. K.
Polcerova, L.
Polepally, A. R.
496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
1994 - Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
1994 - Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Poletti, A.
Polgarova, K.
1711 - PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial
1713 - BMI and Its Changes As a Predictor of Survival in DLBCL Patients
1992 - First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
3012 - Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?
1713 - BMI and Its Changes As a Predictor of Survival in DLBCL Patients
1992 - First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
3012 - Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?
Policastro, A.
Polido, G.
Polin, L.
Polinsky, M.
Polizzi, S.
Polizzotto, M. N.
Poll, P.
Pollack, C.
Pollak, M.
Pollard, J. A.
Pollard, J.
Pollmann, C.
Pollyea, D. A.
62 - Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML
969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy
1008 - IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
2722 - STAT3-VDAC1 Axis Modulates Mitochondrial Function and Plays a Critical Role in the Survival of Leukemic Stem Cells
3803 - Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)
4259 - Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia
4266 - Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia
4312 - PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy
1008 - IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
2722 - STAT3-VDAC1 Axis Modulates Mitochondrial Function and Plays a Critical Role in the Survival of Leukemic Stem Cells
3803 - Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)
4259 - Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia
4266 - Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia
4312 - PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
Pollyea, D. A.
Polo, M.
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
4285 - Optimal Timing for Response Assessment in Acute Myeloid Leukemia Patients Treated with CPX-351 Induction: Real World Experience from 8 Spanish Hospitals
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
4285 - Optimal Timing for Response Assessment in Acute Myeloid Leukemia Patients Treated with CPX-351 Induction: Real World Experience from 8 Spanish Hospitals
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Polo, M.
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
Pölönen, P.
325 - Genetic and Functional Characterization of NUP98-Rearranged Leukemia
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia
Poloni, A.
2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
3323 - Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis
3800 - Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms
3323 - Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis
3800 - Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms
Polonskaia, A.
Polpichai, N.
Polprasert, C.
Polski-Delve, A. N.
Poluben, L.
Polverelli, N.
3559 - Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
Polverelli, N.
2168 - HLA-DQ8 Haplotype Increases the Risk of Relapse after Allogeneic Stem Cell Transplantation Possibly Affecting Graft-Versus-Leukemia: A Single-Center Study on 400 Patients
3520 - Endothelial Dysfunction and Risk of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: END-GAME Prospective Study Final Results
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
4797 - Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study
3520 - Endothelial Dysfunction and Risk of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: END-GAME Prospective Study Final Results
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
4797 - Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study
Polychronopoulou, S.
Polychronopoulou, S.
Pomares, H.
225 - Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations
597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
1838 - Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group
2708 - Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
1838 - Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group
2708 - Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
Pomerance, L.
Pomerantz, R.
Pomicter, T.
Pomilio, G.
Pompilus, F.
Ponce, D. M.
Poncz, M.
185 - Antiphospholipid Syndrome (APS) Is a Platelet Factor 4 (PF4)-Centric Immunothrombotic Disorder
424 - Mechanistic Insights and Clinical Implications of the Thrombotic Risks of a Highly Prevalent GRK5 Variant Affecting Platelets
1231 - Platelet Factor 4 Enhances Endothelial Cell Antimicrobial Activity in Vitro and Promotes Bacterial Clearance In Vivo, Improving Sepsis Outcomes
2528 - Why Do Peptidyl Arginine Deiminase (PAD) 4-Deficient Mice Have Improved Survival Following Cecal Ligation and Puncture (CLP) Sepsis? Implications for the Role Neutrophil Extracellular Trap (NETs) in Immune Homeostasis
3986 - Platelet Factor 4 (PF4) Binding to Neutrophil Extracellular Traps (NETs) and Von Willebrand Factor (vWF) Improves Bacterial Capture and Killing in an Electrostatic Charge-Dependent Manner
424 - Mechanistic Insights and Clinical Implications of the Thrombotic Risks of a Highly Prevalent GRK5 Variant Affecting Platelets
1231 - Platelet Factor 4 Enhances Endothelial Cell Antimicrobial Activity in Vitro and Promotes Bacterial Clearance In Vivo, Improving Sepsis Outcomes
2528 - Why Do Peptidyl Arginine Deiminase (PAD) 4-Deficient Mice Have Improved Survival Following Cecal Ligation and Puncture (CLP) Sepsis? Implications for the Role Neutrophil Extracellular Trap (NETs) in Immune Homeostasis
3986 - Platelet Factor 4 (PF4) Binding to Neutrophil Extracellular Traps (NETs) and Von Willebrand Factor (vWF) Improves Bacterial Capture and Killing in an Electrostatic Charge-Dependent Manner
Poncz, M.
2605 - Complement Activation As a Biomarker for Platelet Activating Antibodies in Heparin-Induced Thrombocytopenia (HIT)
2606 - The PF4-Centric Immunothrombotic Disorders, HIT, Vitt and APS, Lead to Complement Activation Responsive to Complement-Blocking Therapeutics
2611 - Anti-Phospholipid Syndrome (APS) Antibody (Ab)-Induced Thrombosis Can be Blocked By Platelet Factor 4 (PF4)-Directed Abs: A Novel Therapeutic Approach for APS?
2606 - The PF4-Centric Immunothrombotic Disorders, HIT, Vitt and APS, Lead to Complement Activation Responsive to Complement-Blocking Therapeutics
2611 - Anti-Phospholipid Syndrome (APS) Antibody (Ab)-Induced Thrombosis Can be Blocked By Platelet Factor 4 (PF4)-Directed Abs: A Novel Therapeutic Approach for APS?
Pond, G. R.
703 - Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
704 - Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
3749 - Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy
3753 - Longitudinal Changes in Cognition in Older Individuals Receiving Lymphoma-Directed Therapy: A Pilot Feasibility Study
4878 - Patient Characteristics and Outcomes of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Patients - a Multicenter Canadian Study
5170c - Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada
704 - Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
3749 - Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy
3753 - Longitudinal Changes in Cognition in Older Individuals Receiving Lymphoma-Directed Therapy: A Pilot Feasibility Study
4878 - Patient Characteristics and Outcomes of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Patients - a Multicenter Canadian Study
5170c - Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada
Pongas, G.
Pongas, G.
Poniatowski, J.
Pont, M. J.
93 - Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
3452 - Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
3452 - Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
Pontes, L.
Pontikoglou, C.
Ponvilawan, B.
Ponvilawan, B.
2172 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged over 70 Years with Myelofibrosis
3556 - Socioeconomic Disparities in Allogeneic Hematopoietic Cell Transplant Outcomes
4670 - Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Patients with Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis
4936 - Correlates of Patient-Reported Outcomes Following Allogeneic Unrelated Donor Hematopoietic Stem Cell Transplantation
3556 - Socioeconomic Disparities in Allogeneic Hematopoietic Cell Transplant Outcomes
4670 - Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Patients with Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis
4936 - Correlates of Patient-Reported Outcomes Following Allogeneic Unrelated Donor Hematopoietic Stem Cell Transplantation
Ponzar, N.
Ponzo, M.
Ponzoni, M.
Poon, A. C. H.
Poon, L.
3004 - Spatial-Resolved Transcriptomics Reveals Immune Landscape Variations in Primary Central Nervous System Lymphoma (PCNSL) and Diffuse Large B-Cell Lymphoma (DLBCL)
3602 - Machine Learning Classification of Spatial Patterns of Malignant Cells Reveals Implications in Prognosis and Tumor Microenvironment Composition in Lymphoma
3602 - Machine Learning Classification of Spatial Patterns of Malignant Cells Reveals Implications in Prognosis and Tumor Microenvironment Composition in Lymphoma
Poon, M. C.
Poon, M. L.
388 - Evaluating the Comprehensive Geriatric Assessment Model As an Assessment Tool to Predict Chemotoxicity in Elderly Patients with Lymphoma
1737 - Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial
3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies
3660 - Outcomes of Elderly Patients with DLBCL and Utility of Geriatric Assessment Tools to Predict Chemotoxicity
1737 - Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial
3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies
3660 - Outcomes of Elderly Patients with DLBCL and Utility of Geriatric Assessment Tools to Predict Chemotoxicity
Poorebrahim, M.
591 - NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
1892 - Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma
4642 - Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma
4651 - BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
1892 - Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma
4642 - Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma
4651 - BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma
Poort, V. M.
Poos, A. M.
248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
766 - Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
1607 - Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy
3276 - Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
766 - Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
1607 - Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy
3276 - Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
Popa, M.
Popat, R.
677 - Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial
704 - Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
1960 - Automated Body Composition Analyses Reveal Significant Associations with Mortality in Myeloma Patients Following Immunotherapy with Bispecific Antibodies
1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
3355 - Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
3792b - Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group
4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
4744 - Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
704 - Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
1960 - Automated Body Composition Analyses Reveal Significant Associations with Mortality in Myeloma Patients Following Immunotherapy with Bispecific Antibodies
1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
3355 - Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
3792b - Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group
4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
4744 - Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
Popat, U.
506 - Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial
924 - TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial
1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1497 - Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1922 - Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
1923 - Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
2191 - Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy
2810 - Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
3514 - Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
3926 - Large Scale Manufacturing of GMP Grade Cord Blood Derived Megakaryocytes for Chemotherapy Induced Thrombocytopenia
4841 - Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies
4890 - Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide
924 - TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial
1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1497 - Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1922 - Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
1923 - Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
2191 - Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy
2810 - Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
3514 - Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
3926 - Large Scale Manufacturing of GMP Grade Cord Blood Derived Megakaryocytes for Chemotherapy Induced Thrombocytopenia
4841 - Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies
4890 - Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide
Popescu, B.
Pophali, P.
Pophali, P. A.
71 - Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)
111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
4415 - A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
4415 - A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Popkova, T.
1887 - Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
1962 - Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients
1999 - A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma
3270 - Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma
5156 - Teclistamab in Relapsed and Refractory Multiple Myeloma Patients – Czech Multi-Center Real World Evidence Analysis
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
1962 - Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients
1999 - A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma
3270 - Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma
5156 - Teclistamab in Relapsed and Refractory Multiple Myeloma Patients – Czech Multi-Center Real World Evidence Analysis
Poplineau, M.
Popov, V. M.
Popova, N.
Popovsky, M. A.
Popp, N. A.
Popplewell, L. L.
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4398 - Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry
LBA-6 - Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4398 - Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry
LBA-6 - Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial
Popradi, G.
Porazzi, P.
4 - Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate
504 - Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies
4792 - EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors
504 - Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies
4792 - EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors
Porcelijn, L.
Porcu, P.
466 - Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial
980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
1609 - Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial
3063 - The Risk of Developing Non-Melanoma Skin Cancers in Patients with Cutaneous T-Cell Lymphoma
5094 - Real-World Data Shows Increased Incidence of Autoimmune Disease in Survivors of Childhood Lymphoid Malignancies
5111 - Comparison of Zanubrutinib and Ibrutinib As Treatments for Waldenstrom Macroglobulinemia: A Real-World Retrospective Study
980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
1609 - Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial
3063 - The Risk of Developing Non-Melanoma Skin Cancers in Patients with Cutaneous T-Cell Lymphoma
5094 - Real-World Data Shows Increased Incidence of Autoimmune Disease in Survivors of Childhood Lymphoid Malignancies
5111 - Comparison of Zanubrutinib and Ibrutinib As Treatments for Waldenstrom Macroglobulinemia: A Real-World Retrospective Study
Porkka, K.
329 - Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity
1476 - Deep Learning Models for Predicting Overall Survival of Acute Myeloid Leukemia Using Short-Term Longitudinal Blood Measurements and the Omop Common Data Model
1529 - Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes
1560 - Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
1780 - Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML
3612 - Enabling Population-Scale Screening of Myeloid Neoplasms Using Blood Cell Count Dynamics
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
1476 - Deep Learning Models for Predicting Overall Survival of Acute Myeloid Leukemia Using Short-Term Longitudinal Blood Measurements and the Omop Common Data Model
1529 - Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes
1560 - Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
1780 - Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML
3612 - Enabling Population-Scale Screening of Myeloid Neoplasms Using Blood Cell Count Dynamics
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
Porrata, L.
Portell, C. A.
Portell, C. A.
3101 - Durability of Complete Responses in Patients from the ECHELON-3 Study
4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4489 - Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4489 - Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
Porter, A. H.
Porter, C. C.
Porter, D. L.
588 - Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy
909 - BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function
2275 - Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone
4503 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
5123 - Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2nd Line CAR T Therapy
909 - BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function
2275 - Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone
4503 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
5123 - Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2nd Line CAR T Therapy
Porter, J.
Porter, J. B.
409 - ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
2475 - Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE Trial
3895 - Observational Data on Parvovirus B19 Cases in Patients with Red Cell Disorders in the United Kingdom from 2023-2024
2475 - Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE Trial
3895 - Observational Data on Parvovirus B19 Cases in Patients with Red Cell Disorders in the United Kingdom from 2023-2024
Porteus, M.
2015 - Evaluation of Bone Marrow in Fanconi Anemia Patients Treated with Briquilimab Antibody-Based Conditioning and TCRαβ+ T-Cell/CD19+ B-Cell Depleted Haploidentical Grafts
3525 - T-allo10 Immunotherapy Results in Enhanced Early Immune Reconstitution and Reduced GvHD with Excellent Clinical Outcomes Post Αβ-Depleted HSCT in Pediatric and Young Adult Hematologic Malignancy Patients
3525 - T-allo10 Immunotherapy Results in Enhanced Early Immune Reconstitution and Reduced GvHD with Excellent Clinical Outcomes Post Αβ-Depleted HSCT in Pediatric and Young Adult Hematologic Malignancy Patients
Porteus, M. H.
Portlock, C. S.
Portola, P.
Ports, M. O.
Portugues, C.
4467 - Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial
Portuguese, A. J.
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
3772 - Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
3772 - Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
Portuguese, A. J.
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
Porubsky, S.
Porwit, A.
Posey, A. D.
Posma, J.
Pospelova, T. I.
Pospíšilová, D.
Pospisilova, D.
Pospisilova, S.
Pospistle, A.
Post, G. R.
Postek, M.
Postich, E.
253 - Evolution of Clonal Hematopoiesis after Discontinuation of Therapy for Multiple
308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
1429 - Clinical Implications of Treatment-Related Clonal Hematopoiesis in Adolescent and Young Adult Survivors of Acute Lymphoblastic Leukemia
308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
1429 - Clinical Implications of Treatment-Related Clonal Hematopoiesis in Adolescent and Young Adult Survivors of Acute Lymphoblastic Leukemia
Postigo Camps, M.
Poston, J. N.
Poston, L.
Postorino, M.
Postovalova, E.
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma
4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma
Potere, N.
Potezny, T.
Potgieter, J.
Pothacamury, R. K.
Potluri, G.
Potluri, R.
Potnis, K. C.
3644 - Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
3669 - Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule
3669 - Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule
Pott, C.
114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
237 - Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
2959 - Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure
4352 - Determining the Mutational Landscape of Waldenström’s Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström’s Macroglobulinemia
3042.2 - Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy – MCL Elderly III
4422.3 - Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)
237 - Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
2959 - Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure
4352 - Determining the Mutational Landscape of Waldenström’s Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström’s Macroglobulinemia
3042.2 - Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy – MCL Elderly III
4422.3 - Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)
Potter, B.
Potter, M.
Potter, N.
Potter, N.
Potter, V.
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
600 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4950 - Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
600 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4950 - Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP
Pottez-Jouatte, V.
Potts, C. R.
Pötzsch, B.
Pou, S.
Poulain, S.
Pouli, A.
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
Poulides, N.
Pouliot, O.
521 - Baseline Neurological Morbidity Assessment in Adult Patients with Sickle Cell Disease : The Montreal Brain-SCD Cohort
804 - Lifetime Prevalence of Stroke within an Adult Population with Sickle Cell Disease: A Cross-Sectional Study
3883 - Systematic Transcranial Doppler Examination in Adults with Sickle Cell Disease : A Cross-Sectional Single Center Study
804 - Lifetime Prevalence of Stroke within an Adult Population with Sickle Cell Disease: A Cross-Sectional Study
3883 - Systematic Transcranial Doppler Examination in Adults with Sickle Cell Disease : A Cross-Sectional Single Center Study
Poullet, A.
Poullin, P.
Poulose, J.
Poulsen, C.
Poulsen, C. B.
235 - Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich
650 - Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group
654 - Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study
883 - Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
888 - Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients
3099 - Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
3243 - Safety of Venetoclax Ramp-up before CD20 Antibody Administration in Chronic Lymphocytic Leukemia
4609 - Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial
650 - Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group
654 - Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study
883 - Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
888 - Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients
3099 - Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
3243 - Safety of Venetoclax Ramp-up before CD20 Antibody Administration in Chronic Lymphocytic Leukemia
4609 - Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial
Poulsen, L. Ø.
Poulsen, O.
Poulton, K.
925 - The Influence of HLA Matching of the Winning and Losing Units in Relapse of Patients Receiving Double Cord Blood Transplantation for Acute Leukemia or Myelodysplastic Syndrome
3455 - Reproducible Transient, Significant, Early Donor-Derived T-Cell Expansion, Induced By Pooled Granulocyte Transfusion, during Mismatch T-Cell Replete Cord Blood Transplant - an Optimal Platform for Allogeneic Graft Versus Leukaemia: Results of a Prospective Phase I/II Clinical Trial
3455 - Reproducible Transient, Significant, Early Donor-Derived T-Cell Expansion, Induced By Pooled Granulocyte Transfusion, during Mismatch T-Cell Replete Cord Blood Transplant - an Optimal Platform for Allogeneic Graft Versus Leukaemia: Results of a Prospective Phase I/II Clinical Trial
Pounds, S.
103 - Rapid Long-Read Epigenomic Diagnosis and Prognosis of Acute Myeloid Leukemia
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
4327 - Genome-Wide Association Study of Metabolites in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia Identified Novel Metabolite Quantitative Trait Loci
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
4327 - Genome-Wide Association Study of Metabolites in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia Identified Novel Metabolite Quantitative Trait Loci
Pour, L.
362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
1992 - First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
1999 - A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma
2378 - Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets – Analysis of the Czech Myeloma Group
3352 - Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study
4731 - Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
5156 - Teclistamab in Relapsed and Refractory Multiple Myeloma Patients – Czech Multi-Center Real World Evidence Analysis
1992 - First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
1999 - A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma
2378 - Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets – Analysis of the Czech Myeloma Group
3352 - Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study
4731 - Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
5156 - Teclistamab in Relapsed and Refractory Multiple Myeloma Patients – Czech Multi-Center Real World Evidence Analysis
Pourdehnad, M.
677 - Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial
869 - Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
3018 - Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study
3104 - Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome
869 - Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
3018 - Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study
3104 - Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome
Pourebrahim, R.
Pourhassan, H.
729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
4264 - Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
4264 - Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
Pourjam, M.
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Poveda Garcia, A.
Powell, B. L.
641 - Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment
2858 - The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
2858 - The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
Powell, C.
Powell, D. R.
Powell, E.
Powell, J.
Powell, S.
Power, B.
Power, K.
Power, L. C.
Power-Hays, A.
542 - Hydroxyurea Pharmacokinetics in Children with Sickle Cell Anemia: Comparison of Global Cohorts
546 - Hydroxyurea Decreases Transfusion Utilization in Ugandan Children with Sickle Cell Anemia: Main Results from the Alternative Dosing and Prevention of Transfusions (ADAPT) Trial
3682 - Ketamine Use in Hospitalized Children and Young Adults with Sickle Cell Disease
- Alternative Dosing and Prevention of Transfusions (ADAPT): A Prospective Trial to Quantify the Change in Blood Transfusion Use with Hydroxyurea Treatment and the Feasibility of Pharmacokinetic-Guided Dosing in Children with Sickle Cell Anemia in Uganda
- The Importance of Recognition of Pediatric Quality Metrics in SCD: The Role of US News and World Report
546 - Hydroxyurea Decreases Transfusion Utilization in Ugandan Children with Sickle Cell Anemia: Main Results from the Alternative Dosing and Prevention of Transfusions (ADAPT) Trial
3682 - Ketamine Use in Hospitalized Children and Young Adults with Sickle Cell Disease
- Alternative Dosing and Prevention of Transfusions (ADAPT): A Prospective Trial to Quantify the Change in Blood Transfusion Use with Hydroxyurea Treatment and the Feasibility of Pharmacokinetic-Guided Dosing in Children with Sickle Cell Anemia in Uganda
- The Importance of Recognition of Pediatric Quality Metrics in SCD: The Role of US News and World Report
Powers, A.
Powers, H.
Powers, L.
Poynton, E.
Pozek, E.
84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Pozharskaya, V.
350 - Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent–Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial
1818 - Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial
1818 - Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial
Poziopoulos, C.
Pozner, G.
Pozzetto Huot, R.
Pozzi, G.
Pozzi, N.
Pozzi, S.
339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi
2975 - Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization
2975 - Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization
Pozzo, F.
Prabagaran, P.
Prabhala, R.
Prabhu, N.
Prabhu, S.
368 - CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes after CAR T Cell Therapy for LBCL
911 - CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
2817 - Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study
911 - CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
2817 - Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study
Pradhan, A.
750 - Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
1724 - A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
1724 - A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
Pradhan, B.
Pradhan, K.
878 - TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization
943 - Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion
1591 - North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist
2791 - Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma
2909 - Degrading SMARCA2/4 Relieves the Differentiation Block in AML Via Chromatin Alterations Affecting S100A8/9
3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients
3200 - Environmental Pollution Is Associated with Higher Risk MDS in a Diverse Urban Cohort and Triggers Inflammation in a Murine Models
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
943 - Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion
1591 - North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist
2791 - Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma
2909 - Degrading SMARCA2/4 Relieves the Differentiation Block in AML Via Chromatin Alterations Affecting S100A8/9
3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients
3200 - Environmental Pollution Is Associated with Higher Risk MDS in a Diverse Urban Cohort and Triggers Inflammation in a Murine Models
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
Pradillo Fernandez, V.
319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
4285 - Optimal Timing for Response Assessment in Acute Myeloid Leukemia Patients Treated with CPX-351 Induction: Real World Experience from 8 Spanish Hospitals
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
4285 - Optimal Timing for Response Assessment in Acute Myeloid Leukemia Patients Treated with CPX-351 Induction: Real World Experience from 8 Spanish Hospitals
Prajapati, S.
Prajapati, S.
Prakash, G.
Prakash, H.
Prakash, O.
Prakash, R.
455 - An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL
611 - Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data
5127 - Utility of PET/CT Imaging in Predicting Outcomes of Patients with Lymphoid Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis from a Single Tertiary Center
611 - Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data
5127 - Utility of PET/CT Imaging in Predicting Outcomes of Patients with Lymphoid Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis from a Single Tertiary Center
Pramanik, D.
Prange-Krex, G.
Prasad, J.
Prasad, P.
Prasad, T.
Prasai, A.
Pratap Singh, N.
Pratcorona, M.
225 - Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations
2709 - Association of Clonal Hematopoiesis and Dysgranulopoiesis with Germline ETV6 Carriers without Hematological Malignancies
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
2709 - Association of Clonal Hematopoiesis and Dysgranulopoiesis with Germline ETV6 Carriers without Hematological Malignancies
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
Prathikanti, R.
3031 - Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study
3255 - Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
3255 - Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
Prati, D.
Pratt, G.
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
3354 - Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome – Long-Term Follow-up of the Ukmra Optimum/Muknine Trial
3354 - Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome – Long-Term Follow-up of the Ukmra Optimum/Muknine Trial
Pratz, K. W.
221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
1493 - IDH Mutated AML Is Associated with Increased Risk of Pulmonary Morbidity and Mortality during Induction Chemotherapy
2436 - The Use of Antifungal Prophylaxis Is Associated with Worse Outcomes in Patients with Newly Diagnosed AML Treated with Venetoclax/HMA: A Retrospective Analysis of Patients in the Flatiron Health Database
2880 - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
1493 - IDH Mutated AML Is Associated with Increased Risk of Pulmonary Morbidity and Mortality during Induction Chemotherapy
2436 - The Use of Antifungal Prophylaxis Is Associated with Worse Outcomes in Patients with Newly Diagnosed AML Treated with Venetoclax/HMA: A Retrospective Analysis of Patients in the Flatiron Health Database
2880 - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Pray, B. A.
Prchal, J. T.
1758 - Iron Deficiency Correction in Myeloproliferative Neoplasms Reduces Thrombosis Risk Via Decreased P-Selectin
1791 - Quality of Life Evaluation for Patients on Ropeginterferon Alpha-2b Versus Other Best Available Therapies
LBA-4 - Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
1791 - Quality of Life Evaluation for Patients on Ropeginterferon Alpha-2b Versus Other Best Available Therapies
LBA-4 - Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Prchal-Murphy, M.
Prebet, T.
Pregno, P.
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
Pregnolato, M.
Prelog, T.
Prem Kumar, P.
Prem Sudha, S.
Premdeep, H.
Presgrave, P.
1445 - Health-Related Quality of Life in Adolescents and Young Adults Treated with Blinatumomab Consolidation for CD19+ Ph-Negative Acute Lymphoblastic Leukemia in the Australasian Lymphoma and Leukaemia Group (ALLG) ALL09 "Sublime” Study
3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo
3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo
Presles, E.
Press, V. G.
Pressler, M.
Preston, A.
Preston, G.
585 - IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
Prete, E.
Preudhomme, C.
226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network
227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
Preussler, J. M.
3672 - Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial
3680 - Comparing Access to Allogeneic Hematopoietic Cell Transplant across the United States: Physician Density, Minority Health Social Vulnerability Index, Transplant Unmet Need and Utilization
5051 - To Treat or Not to Treat: Factors Associated with Receipt of Allogeneic Hematopoietic Cell Transplant
3680 - Comparing Access to Allogeneic Hematopoietic Cell Transplant across the United States: Physician Density, Minority Health Social Vulnerability Index, Transplant Unmet Need and Utilization
5051 - To Treat or Not to Treat: Factors Associated with Receipt of Allogeneic Hematopoietic Cell Transplant
Preyer, M.
Prezant, D.
Prezioso, C. T.
Prica, A.
1606 - Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
3092 - Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis
3376 - Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
3092 - Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis
3376 - Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
Prica, A.
401 - Disparities in Clinical Trial Enrollment for Patients with Hematologic Malignancies – a 15-Year Princess Margaret Cancer Centre Experience
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
1954 - Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
2352 - Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance
3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3645 - Virtual Care Use for Patients with Hematologic Malignancies – a Natural Policy Experiment
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
3749 - Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy
4385 - Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD
4432 - Anthracycline Exposure and Breast Cancer Risk in Female Hodgkin Lymphoma Survivors
4690 - Handgrip Strength – Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
1954 - Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
2352 - Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance
3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3645 - Virtual Care Use for Patients with Hematologic Malignancies – a Natural Policy Experiment
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
3749 - Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy
4385 - Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD
4432 - Anthracycline Exposure and Breast Cancer Risk in Female Hodgkin Lymphoma Survivors
4690 - Handgrip Strength – Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
Price, E.
Price, J.
Price, P.
Price, V. E.
Price, Z.
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
4596 - Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
4596 - Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure
Priebe, O.
Priego, V.
Prieto, E.
365 - Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
Prieto, I.
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
3123 - BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
3123 - BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
Prieto Martinez, P.
4403 - Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?
Primo, D.
Prin Felix, L.
Prince, E.
Prince, G. T.
1841 - Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (mIDH1) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria
3226 - Improved Hematologic Recovery with Ivosidenib in Patients with mIDH1 Relapsed or Refractory MDS: Results from a Phase 1 Substudy
3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy
3226 - Improved Hematologic Recovery with Ivosidenib in Patients with mIDH1 Relapsed or Refractory MDS: Results from a Phase 1 Substudy
3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy
Prince, H. M.
Prince, H. M.
460 - Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
4486 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B‑Cell Lymphoma Treated with Odronextamab in the ELM-2 Study
4502 - Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study
4738 - MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
4486 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B‑Cell Lymphoma Treated with Odronextamab in the ELM-2 Study
4502 - Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study
4738 - MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
Prince, R.
Princic, N.
Princiotta, M.
Principato, R.
Prinjha, R.
Prinz, M.
856 - Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
4374 - The Effect of Ibrutinib on the Myeloid Cell Compartment in Central Nervous System Lymphoma Slice Cultures
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
4374 - The Effect of Ibrutinib on the Myeloid Cell Compartment in Central Nervous System Lymphoma Slice Cultures
Prior, D.
1063 - Predictors of Graft Failure Beyond 24 Months Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
2302 - Pre-Transplant Liver Fibrosis Predicts Poor Overall Survival Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
2304 - Age at Hematopoietic Cell Transplantation Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Patients with Sickle Cell Disease
2302 - Pre-Transplant Liver Fibrosis Predicts Poor Overall Survival Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
2304 - Age at Hematopoietic Cell Transplantation Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Patients with Sickle Cell Disease
Prior, T.
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
Priore, S. F.
Prischak, S.
4425 - Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
Pro, B.
336 - Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas
1664 - Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy
2340 - Health Disparities in Lived Experiences of Patients with Cutaneous T-Cell Lymphoma: An All of Us Database Analysis
3061 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
3077 - Diagnostic Utility of the 18f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder
3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
5042 - Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma
1664 - Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy
2340 - Health Disparities in Lived Experiences of Patients with Cutaneous T-Cell Lymphoma: An All of Us Database Analysis
3061 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
3077 - Diagnostic Utility of the 18f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder
3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
5042 - Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma
Proano, C.
Probst, S.
Prochazka, L.
Prochazka, T.
Prochazka, V.
Prochazkova, M.
Prochowski Iamurri, A.
Prockop, S. E.
70 - Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein–Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy
3639 - International Clinical Consensus on Leukocyte Adhesion Deficiency-I: A Modified Delphi Analysis
4866 - Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4885 - Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
3639 - International Clinical Consensus on Leukocyte Adhesion Deficiency-I: A Modified Delphi Analysis
4866 - Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4885 - Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
Prokopchuk-Gauk, O. C.
Proli, A.
Pronk, C. J.
Prophete, C.
Proskuriakova, E.
Prosper, F.
670 - An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited
879 - Unveiling ZMAT2 and SMARCD3 As Therapeutic Targets to Mitigate Aberrant Hematopoiesis in MDS
1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
1889 - Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses
4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma
879 - Unveiling ZMAT2 and SMARCD3 As Therapeutic Targets to Mitigate Aberrant Hematopoiesis in MDS
1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
1889 - Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses
4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma
Prosser, A.
Provencio Rincon, A.
Provot, F.
Prozora, S.
Pruett-Miller, S. M.
Pruijt, H.
Pruitt, R. M.
Pruneri, G.
Prus, K.
3626 - Comparison of Utility and Reliability in Low-Resource Laboratory Settings of Low Cost Hemoglobinopathy Point-of-Care Screening Devices
4032 - Low Rate of Red Blood Cell Alloimmunization Among Transfused Children with Sickle Cell Anemia in Malawi without Pre-Transfusion Screening or Antigen Matching
4032 - Low Rate of Red Blood Cell Alloimmunization Among Transfused Children with Sickle Cell Anemia in Malawi without Pre-Transfusion Screening or Antigen Matching
Prussien, K. V.
Pruter, W. W.
Pruthi, R. K.
613 - Assessment of Classical Hematologists and Hematology-Focused Fellowship Programs at NCI-Designated Cancer Centers: Implications for Addressing Workforce Shortages and Enhancing Mentorship Opportunities
1217 - Accuracy of a Bleeding Assessment Tool in Predicting the Diagnosis of an Inherited Bleeding Disorder: Systematic Review and Meta-Analysis
1242 - Ticagrelor Interference in the Serotonin-Release Assay
3996 - Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis
4016 - Potential for False Negative Lupus Anticoagulant Testing in Patients Anticoagulated with Warfarin Using Dilute Russell's Viper Venom Time Assay
1217 - Accuracy of a Bleeding Assessment Tool in Predicting the Diagnosis of an Inherited Bleeding Disorder: Systematic Review and Meta-Analysis
1242 - Ticagrelor Interference in the Serotonin-Release Assay
3996 - Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis
4016 - Potential for False Negative Lupus Anticoagulant Testing in Patients Anticoagulated with Warfarin Using Dilute Russell's Viper Venom Time Assay
Prykhozhij, S. V.
Przemielewska, A.
Przespolewski, A. C.
Przespolewski, E.
Przystupski, D.
Psaila, B.
199 - The Fetal Specific Gene LIN28B Is Essential for Human Fetal B-Lymphopoiesis and Initiation of KMT2A-AFF1+ Infant Acute Lymphoblastic Leukemia
421 - Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity
752 - Amplification of Von Willebrand Factor-Positive CALRmut Disease-Initiating Hematopoietic Stem Cells Is Associated to the Activation of the PERK/EiF2a Branch of Unfolded Protein Response
871 - Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment
876 - Mapping the Human Bone Marrow in Myeloproliferative Neoplasia Using Spatial Transcriptomics
1804 - Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
3146 - RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
3186 - Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib
421 - Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity
752 - Amplification of Von Willebrand Factor-Positive CALRmut Disease-Initiating Hematopoietic Stem Cells Is Associated to the Activation of the PERK/EiF2a Branch of Unfolded Protein Response
871 - Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment
876 - Mapping the Human Bone Marrow in Myeloproliferative Neoplasia Using Spatial Transcriptomics
1804 - Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
3146 - RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
3186 - Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib
Psarros, G.
1927 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3380 - Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3380 - Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
Psimenou, E.
Pu, J. J.
4391 - A Prospective, Multicenter, Single-Arm Study on the Combination of Orelabrutinib and Rituximab in the Second-Line Treatment of Relapsed/Refractory Marginal Zone Lymphoma
4500 - Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring
4500 - Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring
Puccini, B.
578 - Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)
Pucilowska, J.
Pucka, A. Q.
2516 - Self-Administered Acupressure Improves Pain and Quality of Life in Patients with Sickle Cell Disease
2519 - Acupuncture Ameliorates Heightened Inflammatory/Immune Responses Accompanied with Improvement in Clinical Outcomes in Patients with Sickle Cell Disease
3881 - Altered Cerebral Functional Connectivity in Patients with Sickle Cell Disease
2519 - Acupuncture Ameliorates Heightened Inflammatory/Immune Responses Accompanied with Improvement in Clinical Outcomes in Patients with Sickle Cell Disease
3881 - Altered Cerebral Functional Connectivity in Patients with Sickle Cell Disease
Puckrin, R.
Puebla Tornero, L.
Puerta Vazquez, C.
Puertas Martínez, B.
Pufall, M. A.
Pugh, K.
Pugh, T. J.
Pugliese, N.
Pugliese, P.
Puglisi, F.
1471 - Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification
1478 - High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction
4239 - Excellent Outcome in NPM1-mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations
1478 - High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction
4239 - Excellent Outcome in NPM1-mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations
Pui, C. H.
681 - Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia
830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
4208 - Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII
830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
4208 - Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII
Puig, N.
365 - Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
489 - Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis
670 - An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials
4390 - Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)
4694 - Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma
489 - Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis
670 - An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials
4390 - Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)
4694 - Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma
Puigserver, P.
Puissant, A.
Puiu, D.
Pujar, H.
515 - In Vivo HSC Gene Editing for Correction of the Sickle Cell Mutation Using RNA Gene Writers
2197 - Delivery of Gene Writers In Vivo to Hematopoietic Stem Cells and T Cells Using Targeted and Untargeted Lipid Nanoparticles (LNP)
4799 - Targeted Lipid Nanoparticle Delivery of an RNA Gene Writer In Vivo Enables Generation of CAR-T Cells in a Humanized Mouse Model
2197 - Delivery of Gene Writers In Vivo to Hematopoietic Stem Cells and T Cells Using Targeted and Untargeted Lipid Nanoparticles (LNP)
4799 - Targeted Lipid Nanoparticle Delivery of an RNA Gene Writer In Vivo Enables Generation of CAR-T Cells in a Humanized Mouse Model
Pujol Fernández, P.
Pula, A.
Pula, A.
Pula, B. M.
773 - Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
2854 - The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)
3242 - MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)
2854 - The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)
3242 - MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)
Pule, M.
Pule, M. A.
871 - Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment
963 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes
3458 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence
4845 - Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial
963 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes
3458 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence
4845 - Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial
Pulido, M.
Pulikkottil, A. J.
Pullarkat, S.
Pullarkat, V.
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
966 - CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study
1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
966 - CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study
1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
Pulles, A. E.
Pullman, W.
4072 - Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
4081 - Population Pharmacokinetics/Pharmacodynamics and Clinical Pharmacology of Zaltenibart (OMS906) in Healthy Subjects and Patients with PNH
4081 - Population Pharmacokinetics/Pharmacodynamics and Clinical Pharmacology of Zaltenibart (OMS906) in Healthy Subjects and Patients with PNH
Pulluru, R.
Pulsipher, M. A.
3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)
4827 - Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia
4827 - Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia
Pulsoni, A.
1639 - Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi
3020 - Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study
4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
3020 - Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study
4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
Pulte, D. D.
1829 - Response Rate, Event-Free Survival (EFS), and Overall Survival in Higher-Risk Myelodysplastic Syndromes (MDS): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses
2416 - FDA Analysis of Enrollment of Pediatric and AYA Patients in Clinical Trials By Race and Ethnicity
3806 - FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome
2416 - FDA Analysis of Enrollment of Pediatric and AYA Patients in Clinical Trials By Race and Ethnicity
3806 - FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome
Pumiglia, E.
Punatar, S.
852 - Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
2953 - Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients
3161 - Making Treatment Free Remission “Feasible” in Low- and Middle- Income Countries - Outcomes, Patterns of Failure and Compliance of Treatment Free Remission (TFR) in Chronic Myeloid Leukemia (CML) from a Tertiary Care Cancer Centre in India
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)
4901 - Diagnostic Value, Predictive Significance and Kinetics of Fecal Calprotectin in Suspected Acute Gut Gvhd / Gvhd Flare Post Allogeneic Stem Cell Transplant
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
2953 - Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients
3161 - Making Treatment Free Remission “Feasible” in Low- and Middle- Income Countries - Outcomes, Patterns of Failure and Compliance of Treatment Free Remission (TFR) in Chronic Myeloid Leukemia (CML) from a Tertiary Care Cancer Centre in India
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)
4901 - Diagnostic Value, Predictive Significance and Kinetics of Fecal Calprotectin in Suspected Acute Gut Gvhd / Gvhd Flare Post Allogeneic Stem Cell Transplant
Punnachet, T.
Punt, M. C.
129 - Postpartum Hemorrhage in Hemophilia a and B Carriers after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
1208 - The Influence of Postpartum Hemorrhage on the Quality of Life Among Pregnant Hemophilia a and B Carriers: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2595 - Postpartum Hemorrhage in Women with Von Willebrand Disease after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2601 - The Influence of Postpartum Hemorrhage on Patient Reported Outcomes Among Women with Von Willebrand Disease: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
1208 - The Influence of Postpartum Hemorrhage on the Quality of Life Among Pregnant Hemophilia a and B Carriers: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2595 - Postpartum Hemorrhage in Women with Von Willebrand Disease after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2601 - The Influence of Postpartum Hemorrhage on Patient Reported Outcomes Among Women with Von Willebrand Disease: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
Punta, M.
Purcarea, A.
Purdie, D. M.
Pureti, S. A.
Purhonen, M.
1780 - Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
Purins, L.
Purroy, N.
1395 - Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)
4142 - BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53
4142 - BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53
Purser, M.
Purtill, D.
223 - Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry
4928 - Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant
3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry
4928 - Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant
Purushe, J.
Purvey, S.
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
Purwar, R.
Purwar, S.
Pushechnikov, A.
Pushel, I.
Pusic, I.
224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial
695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
Putnik, M.
Putta, M. R.
Puttkammer, J.
Puverel, S.
Puy Garcia, C.
Puyuelo, A.
2129 - Donor Chimerism Monitorization for Relapse Prediction in Ex-Vivo CD34-Selected Allogenic Hematopoietic Stem Cell Transplant
3545 - Long-Term Outcomes and Late Complications of Allogeneic Stem Cell Transplant with CD34+ Positive Selection in Adults with Acute Leukaemia and Myelodysplastic Syndrome: A Single-Centre Study
3545 - Long-Term Outcomes and Late Complications of Allogeneic Stem Cell Transplant with CD34+ Positive Selection in Adults with Acute Leukaemia and Myelodysplastic Syndrome: A Single-Centre Study
Puzio-Kuter, A.
Puzzolo, M. C.
Pyclik, A.
Pyörälä, M.
2757 - Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
Pyörälä, M.